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NanobrachytherapyThanks to their unique optical and physicochemical properties, gold nanoparticles have gained increased interest
as radiosensitizing, photothermal therapy and optical imaging agents to enhance the effectiveness of cancer de-
tection and therapy. Furthermore, their ability to carry multiple medically relevant radionuclides broadens their
use to nuclear medicine SPECT and PET imaging as well as targeted radionuclide therapy. In this review, we dis-
cuss the radiolabeling process of gold nanoparticles and their use in (multimodal) nuclear medicine imaging to
better understand their specific distribution, uptake and retention in different in vivo cancer models. In addition,
radiolabeled gold nanoparticles enable image-guided therapy is reviewed aswell as the enhancement of targeted
radionuclide therapy and nanobrachytherapy through an increased dose deposition and radiosensitization, as
demonstrated by multiple Monte Carlo studies and experimental in vitro and in vivo studies.
© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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payload of radionuclides. (B) Passive enhanced permeability and retention accumulation
and the active multivalent binding of targeting moieties to cancer-specific receptors
(C) Functionalization with additional chemotherapeutic drugs and/or imaging molecules1. Background
1.1. An introduction in nuclear medicine
Nuclear medicine involves the internal administration of radionu-
clides to diagnose, stage, treat and follow-up of diseases, including can-
cer. Radiopharmaceuticals are developed by linking a radionuclide to a
carrier molecule (also referred to the targeting molecule), which is di-
rected against a cancer-specific antigen or process. The selection of the
suitable radionuclide depends on its specific emission and the intended
application [1]. In more detail, positron (β+ particles)- and gamma-
emitting radionuclides enable 3D positron emission tomography (PET)
and single photon emission computed tomography (SPECT) imaging,
respectively. Consequently, the radiopharmaceutical can be traced in-
side the body providing functional information about specific molecular
and cellular processes in the tumor depending on the carrier molecule,
such as blood flow, metabolism, receptor expression, tumor metastatic
capacity, inflammation, programmed cell death. On the other hand, ra-
dionuclides emitting β− particles (e.g. iodine-131, lutetium-177,
yttrium-90), α-particles (e.g. actinium-225, astatine-221, bismuth-
213, lead-212) or Auger electrons (e.g. iodine-125, iodine-123,
indium-111, terbium-161, gallium-67), which are coupled to a cancer-
targeting molecule, have the potential to deliver a cytotoxic radiation
dose to the cancer cells. This therapeutic strategy is called targeted ra-
dionuclide therapy (TRT). TRT is a rapidly growing field. Some recent
examples are the development of radiolabeled prostate-specific mem-
brane antigen (PSMA) and the approval of [177Lu]Lu-DOTA-TATE to
treat neuroendocrine tumors [2–4]. However, research continues to in-
vestigate how tomaximize the benefit of radionuclide therapies that are
effective and safe for each individual patient [5].
1.2. The potential advantages of nanoparticles in nuclear medicine
A ‘nanomaterial’ is defined as a natural, incidental or manufactured
material with one or more external dimensions in the size range of
1 nm to 100 nm. In this size range, material properties become control-
lable [6]. Hence, nanoparticles can arise in several shapes, such as
spheres, rods, discs, cubes and cages. Furthermore, as the size of the
nanoparticles decreases, their surface area-to-volume ratio is strongly
increasing. Thanks to these specific properties, nanoparticles can offer
a significant contribution to nuclear medicine.
First, a major advantage is the potential of a single nanoparticle to
holdmultiple radionuclides, achievingmuchhigher payloads of radioac-
tivity as compared to a conventional radiopharmaceutical agent that
carries only one or a few radionuclides (Fig. 1A). In fact, Lucas, et al. cal-
culated in a Monte Carlo simulation that nanoparticles containing mul-
tiple β—emitters (yttrium-90, lutetium-177, iodine-131, iodine-124 or
rhenium-188) may deliver a total absorbed radiation dose of >60 Gy
to a solid, non-small-cell lung carcinoma model, which could not be
achieved by antibodies that were each conjugated to a single radionu-
clide [7]. The number of radionuclides needed per nanoparticle to
achieve 100% tumor control strongly depends on the physical properties
of the radionuclide (the physical half-life, the radiation energy and the62penetration depth) and on the biological properties of the nanoparticles
and the tumor (tumor size, the intra-tumoral distribution, the biological
half-life and the uptake kinetics of the nanoparticles).
Second, the predominant theory is that due to their small size, nano-
particles can efficiently extravasate through the gaps between endothelial
cells of the leaky and immature blood vessels into the tumor mass. Fur-
thermore, the decreased level of lymphatic drainage of the interstitial
fluid within the tumor contributes to the nanoparticle tumor retention.
This rationale is known as the enhanced permeability and retention
(EPR) effect and causes the accumulation and prolonged retention of
radiolabeled nanoparticles in the tumor tissue, increasing the tumor radi-
ation dose [8,9]. However, it is important to point out that despite the EPR
effect is tremendously succesful in preclinical animal models, the clinical
efficacy and translation of cancer nanomedicines remains poor, indicating
that the EPR phenomenon is less reliable in human cancers [10–13].
Therefore, interest is growing in the extravasation of nanoparticles into
tumors via active transendothelial pathways, which appears not to be
underestimated. In fact, Sindhwani, et al. demonstrated a very low
frequency of interendothelial gaps in different xenograft models, such as
U87-MG glioblastoma, 4T1 breast cancer, genetically engineered MMTV-
PyMT breast cancer and patient derived breast cancer, as well as in biop-
sies of human ovarian, breast and glioblastima tumors. In contrast, fenes-
trae and vacuoles, which are associated with endothelial transcytosis,
occur much more frequently in the tumor vasculature across all models.
Furthermore, by deactivating active transendothelial transport pathways,
the authors concluded that only 3–25% of nanoparticle tumor entry is
attributed to the passive transport through gaps, depending on the nano-
particle size [14]..
.
N. Daems, C. Michiels, S. Lucas et al. Nuclear Medicine and Biology 100–101 (2021) 61–90Third, the large surface area-to-volume ratio of nanoparticles facilitates
the functionalization of the nanoparticle surface with multiple cancer
targeting molecules, which creates a multivalent effect, promoting an
efficient binding to the tumor cells (Fig. 1B). As a result, the use of
targeted nanoparticles could enhance the delivery of radioactivity to
the tumor, which in turn leads to an improved therapeutic efficacy
[7,15,16].
Besides the use of cancer targeting molecules, conjugation of other
functional moieties to the nanoparticle surface, such as imaging agents
and chemotherapeutic drugs (Fig. 1C) allows the combination of thera-
peutic and diagnostic applications, a field called ‘theranostics’.
Theranostic nanoparticles allow a non-invasive and real-time tracking
of the in vivo distribution of the nanomaterials and can facilitate the
dose and toxicity management [17].
1.3. The benefits of gold nanoparticles in cancer detection en therapy
In addition to the conjugation to multiple functional moieties and
the labelingwith radionuclides as described above, the use of gold nano-
particles (AuNPs) as radionuclide carrier in nuclear medicine has addi-
tional benefits (Fig. 2).
1.3.1. Surface plasmon resonance
One of themost important characteristics of AuNPs involves the sur-
face plasmon resonance (SPR), which occurs when incident light of a
specific wavelength causes a collective and coherent oscillation of free
surface electrons, resulting in the extinction of light and the generation
of heat. As a result, the SPR peak of AuNPs makes them interesting tools
for therapeutic applications, such as photo-thermal therapy (PTT) as
well as for optical imaging applications such as photo-acoustic (PA) im-
aging and surface-enhanced Raman scattering (SERS) [8,18–20]. In
short, due to the conversion of light into heat, AuNPs can efficiently in-
duce localized hyperthermia in the tumor tissue, causing irreversible
damage to the tumor cells [21]. In addition, the heat production causes
a thermo-elastic expansion of the AuNPs and the subsequent emission
of acoustic transients, which can be probed by a transducer to construct
photo-acoustic images [22,23]. Finally, Raman scattering is the inelastic
and specific scattering of photons when they interact with molecules.
The SPR of AuNPs during photon irradiation locally increases theFig. 2.Multifunctional AuNPs and their potential applications in the
63electromagnetic field in the proximity of the nanoparticle surface, dra-
matically enhancing the Raman scattering of a conjugated Raman-
active reporter [24,25].
1.3.2. High atomic number of gold
Second, AuNPs exhibit a high atomic number (Z = 79), causing the
preferential absorption of X-ray photons by the AuNPs compared to
soft tissue. As a result, introducing AuNPs into the body increases the
X-ray attenuation and thus the contrast of the X-ray based images. Cur-
rently, iodine-based compounds are the most frequently used contrast
agents. However, their rapid renal clearance requires short imaging
times and potential catherisation. Furthermore, the increased kidney re-
tention of the contrast media can increase the risk on renal injury. An
additional shortcoming of the iodine-based compounds is the relatively
high viscosity and high osmolality, due to the presence of only 3–6 io-
dine atoms per molecule, which potentially causes a poor patient toler-
ance. In contrast, 1.9 nm sized AuNPs contain 250 gold atoms per
particle, and thus exhibit a much lower osmolality and viscosity at the
same elemental concentration as the iodine agents. Furthermore, the
higher molecular weight of the AuNPs causes a slower blood clearance
as compared to the iodine agents, permitting longer imaging times
after IV injection. Finally, gold has a higher atomic number and absorp-
tion coefficient (79 and 5.16 cm2/g at 100 keV, respectively) as com-
pared to iodine (53 and 1.94 cm2/g at 100 keV, respectively) [26].
In addition, the high atomic number of AuNPs provides a benefit in
radiotherapy. Indeed, the high atomic number of AuNPs causes several
interactions to occur between the X-ray photons and the AuNPs. These
include the photoelectric effect, Compton scattering and pair produc-
tion, which release a burst of secondary electrons, enhancing the
radiation dose deposition inside the tumor volume and thus increasing
the effectiveness of radiotherapy [27]. As a result, radiolabeled gold
nanoparticles have the potential to enhance the dose deposition of the
radionuclides, improving the effectiveness of internal radionuclide
therapy.
1.3.3. Biological effects of gold nanoparticles
Importantly, besides their ability to increase the dose deposition
upon irradiation, AuNPs can also cause biological effects in cancer
cells. Fig. 3 shows potential biological radiosensitization mechanisms
of AuNPs. For example, AuNPs can catalyze the production of ROS anddiagnosis and treatment of cancer. NIR: Near-infrared radiation.
Fig. 3. Different potential biological radiosensitization mechanisms of gold nanoparticles. Based on [28] and [196]. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
Fig. 4. Commonly used cancer types in research to assess the potential of radiolabeled
AuNPs in nuclear medicine imaging and therapy.
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cause mitochondrial dysfunction, DNA damage, autophagy, apoptosis
and G2/M cell cycle arrest, which is the most radiosensitive cell cycle
phase. On the other hand, AuNPs could also inhibit DNA repair mecha-
nisms or destabilize lysosomes, which increases the abundance of
misfolded and aggregated proteins, causing ER stress. [28–42]. As a re-
sult of these biological effects of AuNPs, cancer cells might have a re-
duced capacity to respond adequately to ionizing radiation and are
thus more sensitive to radiotherapy.
In conclusion, radiolabeled AuNPs do not only have the ability to im-
prove nuclearmedicine imaging and therapy by carrying a higher payload
of radionuclides and accumulate in the tumor tissue, but also allows the
combination ofmultiple optical imagingmodalities to improve cancer de-
tection and follow-up. On the other hand, combining multiple treatment
modalities, such as targeted radionuclide therapy, photothermal therapy
and (biological, chemical and physical) radiosensitization, can synergize
the efficacy of the anticancer therapy to combat radio-resistant and/or
chemo-resistant cancer cells [43].
In this review, we will give a broad overview on the radiolabeling
of gold nanoparticles and their potential to improve cancer nuclear
imaging and treatment, taking into account the intratumoral uptake,
retention, biodistribution and the administration method. Further-
more, we will review the dose enhancement and radiosensitizing
potentials of AuNPs in targeted radionuclide therapy and
nanobrachytherapy. The potentials of radiolabeled AuNPs are often
studies in different cancer models in vitro and in vivo, which are
summarized in Fig. 4.
2. Radiolabeling of gold nanoparticles
The radionuclides that are used to radiolabel AuNPs and that are
mentioned in this review are in further detail described in Table 1.
Importantly, a stable association between the radionuclide and the
nanoparticle is essential for the successful implementation of radiolabeled
nanoparticles in cancer diagnosis and therapy. Loss of the radionuclide
can result in its accumulation in non-targeted tissues [45]. In literature,64several methods for nanoparticle radiolabeling have been described
(Fig. 5).
A frequently used strategy is the use of bifunctional chelators, which
strongly complex radiometals. The bifunctional chelators can be directly
attached to the AuNPs via thiolated linkers, for example consisting out
of a glycine-glycine sequence acting as spacer followed by a cysteine res-
Table 1
Useful medical radioisotopes for diagnosis and treatment of cancer-related diseases [44–48].
Isotope Simplified
decay












/ Under investigation for targeted alpha therapy
Yttrium-90 β− Zirconium-90 64.1 h 2.28 (100%) / Microspheres for SIRT of liver cancer
Iodine-131 β− Xenon-131 8.02 d 0.607 (89.6%) 0.365 (81.5%) Treatment of hyperthyroidism, thyroid carcinoma
and NETs





73.8 d 0.672 (47.9%) 0.468 (47.8%) High-dose rate brachytherapy
Gold-198 β− Mercury-198 2.69 d 0.960 (99%) 0.412 (96%) Brachytherapy
Iodine-125 EC Tellurium-125 59.5 d / 0.035 (7%) Low-dose rate brachytherapy
Indium-111 EC Cadmium-111 2.8 d / 0.245 (94%) Scintigraphy of NETs
Zirconium-89 β+
EC




Under investigation for PET imaging
Fluorine-18 β+
EC
Oxygen-18 1.83 h 0.634 (97%) / Routinely used in the form of 2-[18F]FDG as PET-CT





12.7 h 0.653β+ (17.5%)
0.579β- (38.5%)
1.346 (0.47%) Under investigation for PET imaging
Iodine-124 β+
EC






Palladium-103 EC Rhodium-103 17 d / 0.0397
(0.07%)
Brachytherapy permanent implant seeds
Actinium-225 α
β− (later in decay)





Under investigation for targeted alpha therapy
Ytterbium-169 EC Thulium-169 32 d / 0.06312
(44.05%)
High-dose rate brachytherapy
Abbreviations: CT: computed tomography; EC: electron conversion; FDG: fluorodeoxyglucose; NET: neuroendocrine tumor; PET: positron emission tomography; SIRT: selective interna
radiation therapy; SPECT: single-photon emission tomography.
Fig. 5. Radiolabeling of nanoparticles by (A) chelation, (B) incorporation, (C) chemisorption and (D) covalent binding. Based on [45].
Fig. 6. Molecular structure of (A) diethylenetriaminepentaacetic acid (DTPA) and
(B) dodecane tetraacetic acid (DOTA).
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face [49–52]. In addition, the bifunctional chelators can be indirectly at-
tached to the AuNPs via a covalent bond to the nanoparticle coating or
to the vector molecule. In the development of radiopharmaceuticals, a
successful bifunctional chelatorminimizes the dissociation of the radionu-
clide from the chelator in vivo. This depends on the thermodynamic
stability and the kinetic inertness of the bifunctional chelator. The thermo-
dynamic stability reflects the direction of the dissociation reaction, while
the kinetic inertness reflects the rate of the dissociation reaction. Two
well-known bifunctional chelators are diethylenetriaminepentaacetic
acid (DTPA) (Fig. 6A) and dodecane tetraacetic acid (DOTA) (Fig. 6B).
Generally, the ‘open-chain’, acyclic structure of DTPA is typically charac-
terized by fast dissociation kinetics and radiometal complexation. As a re-
sult, DTPA analogs rapidly achieve a high radiochemical yield under mild
reaction conditions. The radiochemical yield is defined as the amount of
activity in the product expressed as the percentage of the starting activity.
A high radiochemical yield is required to obtain a high specific activity,
which in turn is desirable for therapeutic applications [54,55]. However,
the fast dissociation rate and the lower thermodynamic stability of
DTPAmight result in the release of the radionuclide when applied in bio-
logical solutions. Conversely, due to their ‘caged’, macrocyclic construc-
tion, DOTA analogs display a higher thermodynamic stability and are
much more kinetically inert compared to DTPA analogs, creating
radiometal-DOTA complexes that are more likely to retain their chemical
integrity in the presence of natural chelators [53]. However, the
radiolabeling kinetics of DOTA analogs are much slower, requiring65l
elevated temperatures and a longer reaction time to achieve a high yield,
which might affect the integrity of the biomolecules to which it is linked
[56]. DOTA and DTPA analogs are often used to chelate lutetium-177,
indium-111, copper-64 and yttrium-90, radioisotopes suitable for radio-
nuclide therapy [57–61]. On the other hand, technetium-99m is an ideal
radioisotope for SPECT imaging because of its low γ-radiation energy
(140 keV) and short half-life (6.02 h). Next to DTPA and DOTA,
hydrazinonicotinamide (HYNIC) is a suitable chelator to radiolabel
N. Daems, C. Michiels, S. Lucas et al. Nuclear Medicine and Biology 100–101 (2021) 61–90AuNPs with technetium-99m. In the presence of co-ligands, HYNIC forms
monodentate or bidentate coordination bonds with technetium-99m,
achieving a high radiochemical yield and stability [51,52,62,63]. Together
with a good radiochemical yield and radiochemical stability, a high radio-
chemical purity, which measures the presence of other radionuclides
within radiopharmaceutical sample, is a key property of the radiolabeled
nanopharmaceutical product as a diagnostic or therapeutic agent in nu-
clear medicine. The radiochemical yield of radionuclides attached to
AuNPs by using bifunctional chelators can widely range between 30%
and >90%. After purification, the radiochemical purity is always higher
than 95%. The stability can vary from 80% to >95% when incubated in
serum during 24-72 h [51,52,57–60,64–67].
In order to avoid harsh radiolabeling conditions, possible instability
and trans-chelation of the radionuclide, several studies preferred a
chelator-free radiolabelingmethod, incorporating copper-64 and radio-
active gold (gold-198 and gold-199) into the AuNPs during the produc-
tion process [68–76]. 64Cu-doped AuNPs are reported with a
radiochemical yield of nearly 100% after reduction of [64Cu]Cu2+ by hy-
drazine, which reduces to <30% without the use of hydrazine [72]. Fur-
thermore, a stability of 90% to >95% is achieved when the 64Cu-doped
AuNPs are challenged with ethylenediaminetetraacetic acid (EDTA) for
44–48 h [69,71]. In addition, they show 0–8% of degradation or trans-
chelation in serum up to 24-48 h, while the stability of 64Cu[Cu]-DOTA
is less stable [68,69,71]. Importantly, due to direct introduction of
gold-199 or gold-198 into the reaction mixture of AuNPs production,
the incorporation reaches a radiochemical yield as high as 80–96%
[70,74]. In addition, after purification the radiochemical purity is 100%.
In terms of the stability, 198Au-doped and 199Au-doped gold nanostruc-
tures show no dissociation of radioactive gold in serum during a week
[70,74,76].
For radioiodination and radiofluorination of AuNPs, it is possible to
covalently attach radioactive iodine (iodine-124, iodine-125 and
iodine-131) and fluorine-18 to an aromatic phenol group via in situ ox-
idation and substitution [77]. In case of direct radiolabeling, the phenol
group is present into the organic coating of the AuNPs or is provided
by a tyrosine residue being part of an AuNP-conjugated peptide or anti-
body [78–84]. Indirect radiolabeling involves a linker molecule, which
already carries the radiolabeled phenol group and facilitates its coupling
to the AuNPs [85,86]. On the other hand, the phenol-free prosthetic
probes [18F]F‑silicon and [18F]F-bicyclononyne also effectively attach
fluorine-18 to AuNPs [87,88]. Iodination and fluorination are both
rapid radiolabelingmethods achieving a radiochemical yield varying be-
tween 60% to >90% and after purification a purity of >95%. However,
various studies observed some degree of radioiodine release resulting
in a serum stability of the conjugate of 49–76.3% after 48-72 h [83,84].
As a result, the free radionuclides can accumulate in different organs
and increase the dose in healthy tissues, such as in the thyroid, the stom-
ach and the bladder [82]. To address this issue, Lee, et al. constructed a
protective Au-shell around 124I-labeled AuNPs and showed that >98%
of iodine-124 remained on the AuNPs for 48 h in human serum, while
‘unprotected’ AuNPs released 20% or more of iodine-124 [78–80,89,90].
Alternatively, the halogens iodine and astatine possess a strong
affinity for the AuNP surface. As a result, radioactive iodine and the
α-emitter astatine-211 could be attached to the AuNP surface via
chemisorption [91–95]. Interestingly, Dziawer, et al. demonstrated
that 211At-astatinated AuNPs exhibit a radiochemical yield of >99%,
while 131I-iodinated AuNPs show a radiochemical yield ranging
between 64% and >99%. Furthermore, the 211At-astatinated AuNPs dem-
onstrate a better in vitro stability than 131I-iodinated and 125I-iodinated
AuNPs in serum (99% vs 85%–93%) during 24 h [91,92,94,95]. Further-
more, it has been shown that the radioiodine adsorption strength onto
the AuNP surface depends on the AuNP surface modifications and the in-
cubation medium, which could lead to detachment of the radionuclides
andhinder their applications in vivo [96]. In order to reduce iodine detach-
ment from 131I-radiolabeled gold nanorods (AuNRs) in vitro and in vivo,
Wang, et al. pre-oxidized radioactiveNa[131I]I via chloramine T or iodogen66as oxidizing agents to convert sodium iodide to iodine. They demon-
strated that the valence state of iodine significantly affects the adsorption
strength of the radioiodine to AuNRs. Indeed, although both radiolabeled
products have a labeling yield >90%, [131I]I(0)-AuNRs exhibit a high ra-
diochemical stability in vitro (98% in serum for 24 h), with only negligible
uptake of radioiodine in the thyroid of treated mice and a high uptake in
MCF-7 breast cancer cells. In contrast, [131I]I(−1)-AuNRs release the
iodine-131 (a stability of <75% in serum for 24 h), causing considerable
uptake of iodine-131 in the thyroid and bladder of treated mice. To ex-
plain this result, the authors hypothesized that [131I]I(−1) simply adsorbs
onto theAuNRs,while [131I]I(0) reactswith theAuNRs, forming a stronger
bond [97].
3. Assessment of gold nanoparticles in nuclear medicine
3.1. Tumor uptake, retention and distribution
The inherent AuNP characteristics, such as their size, shape, and coat-
ing are determining factors that can affect the AuNP pharmacokinetics,
biodistribution and tumor uptake. Therefore, these properties have to
be carefully tuned in order to maximize the tumor uptake, the tumor-
to-background ratio (T/B), and thus the effectiveness of radiolabeled
AuNPs as diagnostic and therapeutic nano-radiopharmaceuticals. For
this purpose, SPECT, PET and CT are useful imaging tools to better under-
stand the in vivo behavior of radiolabeled AuNPs in real-time. In addition,
inductively coupled plasma-mass spectrometry (ICP-MS), γ-counting
and optical imaging, such as Raman scattering imaging, Cerenkov lumi-
nescence imaging, photoacoustic imaging and fluorescence imaging can
be used to complement the nuclear imaging and to verify the quantity
of AuNPs in the major organs and in the tumor [74,78,90,98–100].
Table 2 represents an overview of the studies using nuclearmedicine im-
aging to assess the tumor uptake, retention and distribution of
radiolabeled gold nanoparticles with respect to their specific characteris-
tics and administration strategies.
3.1.1. Pharmacokinetics and biodistribution
Following administration in vivo, the pharmacokinetics and
biodistribution profile of targeted AuNP-based radiopharmaceuticals,
carrying multiple targeting molecules, substantially differ from the mo-
nomeric radiopharmaceuticals lacking AuNPs (Fig. 7). For instance, the
radiolabeled low-molecular weight monomers, [99mTc]Tc-RGD and
[64Cu]Cu-DOTA-polyethylene glycol (PEG) are cleared from the blood
pool shortly after intravenous (IV) administration (T1/2 < 10 min and
30 min, respectively), whereas [99mTc]Tc-AuNPs-RGD and [64Cu]
Cu‑gold nanoshells (AuNS) exhibit a blood circulation T1/2 of 47 min
and 12.8 h, respectively. Arginine-glycine-aspartate or RGD is a peptide
motif, which is displayed in many extracellular matrix (ECM) proteins
and regulates cell-cell interactions and cell-ECM adhesion. The RGD
peptide can be used as a targeting vector to bind integrins, such as
integrin αvβ3, which is highly expressed on activated endothelial cells
of the tumor neovasculature and on some tumor cells, such as mela-
noma, breast cancer, osteosarcoma and glioma [101]. The blood clear-
ance of the small monomeric radiotracers is followed by early
excretion, mainly via the kidneys and to a lesser extent via the
hepatobiliary pathway, 0-20 h post-injection (Fig. 7 A-B) [102–105].
Unlike small molecules, high molecular weight targeting agents, such
as antibodies, are not excreted via the renal system, but accumulate in the
liver [64,106]. The most important difference in biodistribution pattern is
the significantly higher uptake of the colloidal radiolabeled AuNP analogs
in the liver, spleen and lungs, compared to the low-and high-molecular
weight monomeric systems (Fig. 7 B–C) [51,64,103,106,107]. Excretion
of the radiolabeled AuNPs can take place via both the renal system and
the hepatobiliary system, depending on their size [51,68,103,104,107]
(Fig. 7 A-B). However, Xie, et al. concluded that [64Cu]Cu-AuNS are ex-
creted via the hepatobiliary system at a slower pace than the monomeric
controls [103]. This is potentially due to the sequestration of the AuNPs by
Table 2


















In vivo Targeted SPECT-CT,
in vivo
% ID/g (pos): 3.6–4.0 - .1 | T/M: 7.1–6.9 - 10.0 | T/Bl: 1.0–0.8 -1.6
(1 h - 3 h - 6 h)
% ID/g (blocked): 2.2 /M: 3.9 | T/B: 0.6 (6 h)
% ID/g (neg): 1.3–1.8 .6 | T/M: 2.2–3.3 - 3.7 | T/Bl: 0.5–0.6 - 0.6
(1 h - 3 h - 6 h)
Zhang, et al. [92]







In vivo Combining PET and CLI % ID/g: 5.4 (1 h) - 3.4 h) - 1.8 (24 h)
T/M: ≈4–5 (1 h - 24
Lee, et al. [90]





In vivo PET-CLI detection of
sentinel lymph nodes
SLNs visible 1 h p.i., s ngest signal observed 6 h p.i. Signal
decreased, but still ev ent at 24 h p.i.
% ID/g: ≈30 (1 h) – ≈ 0 (24 h)
Lee, et al. [78]







In vivo targeted SPECT-CT [125I]I-cRP-AuNPs wer localized inside αvβ3-positive U87MG
cells, and were found a negligible amount inside αvβ3-negative
MCF7 cells. [125I]I-cRP uNPs targeted the tumor site effectively
(10 min) -~1 % ID/g ( ). After blocking: tumor was almost
undetectable.












11.1 MBq, 200 μl
In vivo Targeted SPECT-CT of
biodistribution and
tumor uptake
Noticeable tumor upt e after 1 h. Maximal tumor uptake after
6 h. Significantly inhib ed uptake after blocking with free RGD. UT
probed only a low tum ral uptake.
% ID/g (AuNR-T 6 h): 3 (T1/2: 227 min)
% ID/g (AuNP-T 6 h): 3 (T1/2: 80 min)
% ID/g (AuNR-UT 6 h) .67 (T1/2: 213 min)
% ID/G (AuNP-UT 6 h) .5 (T1/2: 95 min)
Zhang, et al. [99]
Iodine-125
Indium-111
















In vivo Characterize MMP
activity, biodistribution
and tumor uptake using
SPECT-CT
125I signal was isolate o the thyroid, stomach, and bladder (4 h)
111In chelation by DTP stable in vivo (4 h)
% ID/g (A431): 7.25 (2 h) – 6.23 (48 h)
% ID/g (4T1Luc): 6.41 4 h) – 10.2 (48 h)
T/M (both tumors):~8 48 h)












In vivo SPECT-CT to track the
in vivo fate of
Trastuzumab-AuNP-111In
after IV and IT injection.
% ID/g (T-IV): 1.23 (48 )
% ID/g (T-IT): 29.59 (4 h)
% ID/g (UT-IV): 2.20 ( h)















In vivo Targeted SPECT-CT to
evaluate the imaging
platform based on AuNPs
Uptake % ID/g (M21): 52
Uptake % ID/g (M21-L 0.39
Uptake % ID/g (U87): 3 (T) – 0.37 (UT)
Ng, et al. [143]
[111In]In-EGF-Au-PEG 32.5 EGF Chelation MDA-MB-468
(pos), human
breast cancer
In vivo SPECT to evaluate tumor
uptake of [111In]
In-EGF-Au-PEG in
Internalization: 11–15 in MDA-MB-468 cells, <2% in 231-H2N
cells (4 h).
% ID/g (pos): 2.81 | % /g (co-EGF): 3.91 (72 h)
Song, et al. [118]































































co-administration of EGF % ID/g (neg): 1.43 | % /g (co-EGF): 1.29 (72 h)
[111In]In-Au@HSANP 213 Albumin Chelation CT-26, mouse
colon carcinoma
IV, IP, 1.7 MBq
In vivo SPECT to investigate the
biodistribution and
tumor uptake.
% ID/g (IV): 0.29–0.33 0.19 - 0.21 | T/M: 9.5–11.1 - 9.3 - 7 (1 h -
24 h - 48 h - 96 h)
% ID/g (IP): 7.77–8.89 3.40 - 1.45 | T/M: 89.4–217.4 - 128.8 - 28.3
(1 h - 24 h - 48 h - 96 )
Chen, et al. [57]
Technetium-99m [99mTc]Tc-AuNP-RGD 21.7 Cyclic RGD Chelation C6, rat glioma
IV and IP,
3.7 MBq, 50 μl
In vivo RVβ3 expression imaging
using targeted SPECT-CT
% ID/g (IV): 3.48–3.65 2.49 - 1.94 (0.5 h - 1 h - 3 h - 24 h);
blocked: 1.46 (1 h)
% ID/g (IP): 2.09–3.28 8.18 - 3.20 (0.5 h - 1 h - 3 h - 24 h);
blocked: 1.18 (1 h)
T/Bl (IV): 7.4 | T/M: 10 | T/Li: 0.2 | T/S: 0.7 (1 h)
T/Bl (IP): 20.5 |T/M: 2 | T/Li: 2.1 | T/S: 3.4 (1 h)












In vivo Sentinel lymph node
detection using targeted
SPECT-CT
% ID (T): 12.99 (1 h) a d 21.02 (24 h)
% ID (UT): 5.41 (1 h) d 13.85 (24 h)
Ocampo-Garcia,
et al. [52]




In vivo Targeted SPECT-CT to
evaluate micrometastasis
% ID lung metastasis ( h): 14.
[99mTc]Tc-AuNP-RGD hieved a 5.2× higher signal in lung
metastases than the [9 Tc]Tc-RGD (1 h).















MRI rSIE (29): (T) 2.4 (UT) 1.5 - (block) 1.5 (4 h)
MRI rSIE (51): (T) 1.6 (UT) 1.3 - (block) 1.4 (4 h)
MRI rSIE (80): (T) 1.5 (UT) 1.3 - (block) 1.4 (4 h)
% ID/g (29): (T) 14.6 UT) 4.0 – (Block) 6.2 (6 h)
% ID/g (51): (T) 9.4 – T) 4.4 – (block) 5.1 (6 h)
% ID/g (80): (T) 8.4 – T) 3.3 – (block) 4.9 (6 h)






Chelation C6, rat glioma
IV, 21 MBq,
150 μl
In vivo targeted SPECT/CT to
evaluate αvβ3 integrin
expressing tumors
T treatment: Increase ignal SPECT (24×) and CT (>2×)
intensities 30 min aft injection compared to UT treatment.
Xu, et al. [65]
{(Au0)6-G2-[99mTc]Tc-DTPA
-PEG-FA} DENPs






In vivo SPECT-CT imaging,
in vivo
T treatment: CT inten y 1.3× higher than after UT treatment
SPECT intensity 2× hi er than after UT treatment, 90 min after
injection








In vitro SPECT-CT imaging of
cancer cells in vitro
Increased acidity (pH 5–5.5), sharply increases the cellular
uptake and the CT and PECT intensities of the T form compared to
UT form.









185 MBq, 0.5 ml
In vivo Sentinel lymph node
(SLNs) detection by
SPECT-CT
The SLNs can be detec d in CT-SPECT imaging at 0.5 h p.i. The
accumulation become righter with time. At 4 h p.i. the SLNs
show accurate delinea on. HU values: 6 (1 h) – 101 (4 h).
Zhao, et al. [63]



















SPECT-CT signal inten ies are much higher in the normal liver
than in the cancer tiss .
HU (T): 47.1 – SPECT: .86 Mbq/mm3 (0.5 h)
HU (UT): 32.6 – SPEC 1.65 MBq/mm3 (0.5 h)
Zhou, et al. [147]
[99mTc]
Tc-AuNP-Lys3-bombesin




In vivo SPECT-CT for in vivo
GRP-receptor imaging
% ID/g (T): 4.30–6.39– 44 (0.5 h - 1 h - 24 h)
T/Bl (T): 5.8 (1 h) – P reas/Bl: 36









Chelation C6, rat glioma
IV, 74 MBq,
100 μl




T treatment: increase PECT (>3×) and CT (1.56×) signal
intensities 2 h–12 h p compared to UT.
UT treatment: no sign intensity changes.
Xing, et al. [62]
































































UT (S): % ID/g: 3.45 - T/M: 10.1 (24 h)
UT (L): % ID/g:~3 - T/M 11.9 (24 h)





Incorporation Orthotopic 4 T1,
mouse breast
cancer IV,
3.7 MBq, 100 μl
In vivo PET imaging of orthotopic
lung tumor and
metastasis
Primary tumor (1 we post implantation):
% ID (monomer): 2.13 T/M: 3.55 (24 h)
% ID (T): 7.15 – T/M: .9 (24 h)
% ID (UT): 3.08 – T/M .79 (24 h)
Metastasis (4 weeks p st implantation):
% ID (monomer): 0.65 24 h)
% ID (T): 7.36 - L/M: 2 1 (24 h)
% ID (UT): 0.79 (24 h)
Zhao, et al. [68]





In vivo PET imaging of
biodistribution and
tumor-targeting efficacy
% ID (T): 6.4–4.6 - 3.3 2.2 (1 h - 5 h - 24 h - 48 h)
% ID (UT): 6.4–5.3 - 3. - 1.8 (1 h - 5 h - 24 h - 48 h)
T/M (T): 16.6 (5 h) – 6 (48 h)
Xiao, et al. [148]









Tumor uptake was no ignificant after 1 h, but increased over
time and plateaued af r 20 h. The majority of accumulated
particles still at the tu or site after 44 h.
% ID/g [64Cu]Cu-AuNS .77 (46 h)
% ID/g [64Cu]Cu-DOTA PEG): 0.1–0.15 (46 h)
Xie, et al. [103]








In vivo PET/CT imaging of tumor
accumulation in SCC-4 for
image-guided PTT in
HCT116 colorectal cancer
No obvious accumulat n at 1 h p.i. [64Cu]Cu-AuNS-RGDfK
accumulated in the tu or at 4 h p.i.
Maximal accumulatio t 20 h p.i. Gradual decline at 44 h p.i.
UT AuNS accumulatio ess pronounced during each time point.









In vivo PET-CT imaging:
biodistribution and EPR
tumor targeting of two
differently sized AuNCs
% ID/g (L): <2 (1 h–2 h)
T/M (L): 4.13–11.9 - 1 8 (1 h–4 h-24 h)
T/Bl (L): 0.30–1.20 (1 –24 h)
% ID/g (S): 2.68–7.2 - (1 h–4 h-24 h)
T/M (S): 25.7 (24 h)
T/Bl (S): 0.14–5.15 (1 –24 h)
Wang, et al. [59]
Pd[64Cu]
Cu@AuTripods-PEG-DAPTA







3.7 MBq, 100 μl
In vivo PET/CT of biodistribution
and tumor uptake for
image-guided PTT
% ID/g (T): 5.19–11.2 h–24 h)
% ID/g (UT): 4.64–6.83 4 h - 24 h)
SUV PET (T): 2.18 (24 )
SUV PET (UT): 1.47 (2 h)
SUV PET (T-blocked): 59 (24 h)
T/M (T): 28.6 (24 h); .7 (SUV PET)
T/M (UT): 5.28 (24 h) .84 (SUV PET)
T/M (T-blocked): 7.89 SUV PET) (24 h)
T/Bl (T): 5.70 (24 h)
T/Bl (UT): 1.82 (24 h)














In vivo PET/CT of biodistribution
and tumor uptake
% ID/g (T): 4.57 (24 h
% ID/g (T blocked): 3.5 (24 h)
% ID/g (T+): 7.43–7.5 (24 h–48 h)
% ID/g (T+ blocked): 8 (24 h)
% ID/g (UT): 3.40 (24
T/M (T): 20.26 (24 h)
T/M (T+): 19.67–30.4 (24 h–48 h)
T/M (UT): 10.11 (24 h
Zhao, et al. [149]







In vivo PET-CT to assess
biodistribution for future
PTT
IT: high tumor concen ations up to 44 h % ID/g: 6.28 (46 h)
IV: much lower amou of AuNS in tumor, slow increase over time
% ID/g: 0.77 (46 h)
Xie, et al. [111]






IV, 25 MBq, 1 ml
IA, 23 MBq,
In vivo PET-CT to compare tumor
uptake of HAuNS after IV
and IA administration
% ID/g (IV-T): 0.16–0. (1 h–24 h) | T/Li: 0.79 - T/M: 13.54 (1 h)
% ID/g (IV-UT): 0.22–0 3 (1 h–24 h) | T/Li: 1.11 - T/M: 17.37 (1 h)
% ID/g (IA-T): 0.20 (1 24 h) | T/Li: 0.81 - T/M: 12.74 (1 h)
% ID/g (IA-UT): 0.13–0 0 (1 h–24 h) | T/Li: 0.81 - T/M: 14.16 (1 h)
% ID/g (IA-UT + oil): 51–0.33 (1 h–24 h) | T/Li: 4.17 - T/M:
Tian, et al. [126]




















































































In vivo Targeted PET and MRI
imaging
% ID/g: 3.5 (4 h) - 4.6 4 h) | T/M: 6 (4-48 h)
% ID/g (blocked): 1.9 4 h) | T/M: 2 (4-48 h)
44% decrease in MRI s nal intensity 48 h after injection of T. No
decrease in MRI signa tensity after blocking.









In vivo PET imaging % ID/g: ~0.8 (1 h) - ~ (24 h) for both
T/M: ~0.5 (1 h) – ~2.5 24 h) for both
heterogeneous distrib ion of radioactivity across the tumor mass
Zhao, et al. [75]




In vivo Improving PET-CT
accuracy and
radiolabeling stability
Stable in mouse serum ithout degradation up to 48 h%
ID/g: 4.93 (1 h) – 16. 48 h)
T/M: 3.99 (1 h) – 11.9 24 h) - 16.2 (48 h)
Zhao, et al. [71]





In vivo Targeted PET-CT for
future image-guided PTT
% ID/g (T): 5–8 - 8.37 .6 (4 h - 16 h - 24 h - 45 h)
% ID/g (blocked): 6.17 24 h)
% ID/g (UT): 6.19 (24












In vivo PET-CT to investigate
biodistribution of AuNPs
% ID/g (NDM/Tw20): 9 (24 h)
% ID/g (PEG): 3.89 (24 )
% ID/g (S/QA): negligi e
Frellsen, et al. [69]




In vivo PET-CT to visualize NP
uptake in tumors after
ablation
SUV tumor (E): 13.9– .1 (1 h–18 h) | T/Li: 1.1–1.7 (1 h–18 h)
SUV tumor (E + RFA 21.5–13.6 (1 h–18 h) | T/Li: 4.7–1.4
(1 h–18 h)
SUV tumor (E + IRE) 2.6–12.3 (1 h–18 h) | T/Li: 0.81–2
(1 h–18 h)
SUV tumor (E + LITT 4.8–17.9 (1 h–18 h) | T/Li: 2–1.5
(1 h–18 h)
















% ID/ml (T): 4.6 (24 h
% ID/ml (blocked): 1.9 6 h)
% ID/ml (CD105-89Zr) .5 (24 h)

















% ID/ml (T): 3.3 (48 h
% ID/ml (Blocked): 1.5 48 h)
% ID/ml (Ctxb-89Zr): 3 (48 h)
T/B (T): 12 (48 h), >2 (168 h)
T/B (blocked): 3.4 (48 )
T/B (Ctxb-89Zr): < 10 8 h), <20 (168 h)
Karmani, et al.
[106]
Abbreviations: Ac: acetylated; Au@AuCB: crushed gold shell gold core nanoballs; AuNC: gold nanocluster; AuNP: gold nanoparticle; AuNR: gold nanorod; Au-PENPs: polyet lenimine-entrapped gold nanoparticles; APAS: alkoxyphenyl
acylsulfonamide; cRP: cRGD-PEG; CLI: Cerenkov luminescent imaging; CT: computed tomography; DAPTA: D-Ala1-peptide T-amide; Au-DENPs: dendrimer-entrap d gold nanoparticles; DOX: doxorubicin; DOTA: 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid; DTPA: diethylenetriaminepentaacetic acid; DTX: docetaxel; E: embolization; EGF: epidermal growth factor; EGFR: epiderma rowth factor receptor; gly: glycol monomethyl; FA: folic acid;
HAuNS: hollow gold nanoshells; Au@HSANP: gold nanocore-encapsulated human serum albumin nanoparticle; HU: Hounsfield unit; IA: intra-arterial; IONP: iron oxide nanop rticle; IP: intraperitoneal; IRE: irreversible electroporation; IT:
intratumoral; IV: intravenous; L: large; LITT: laser induced thermal therapy; L/M: lung-to-muscle ratio; MRI: magnetic resonance imaging; NDM/Tw20: 1-dodecanethiol/tween 20 NOTA: 2-S-(4-isothiocyanatobenzyl)-1, 4, 7-triazacyclononane-
1, 4, 7-triacetic acid; AuNS: gold nanoshells; PEG: polyethylene glycol; PET: positron emission tomography; p.i.: post-injection; PTT: photo-thermal therapy; pMMP9: matrix metall roteinase-9 cleavable peptide; MSH: α-melanocyte-stimulating
hormone; PPAA: plasma-polymerized allylamine; RFA: radiofrequency ablation; rSIE: relative signal intensity enhancement; S: small; SLN: sentinel lymphnode; SPECT: single photon ission computed tomography; SUV: standardized uptake value;
S/QA: sulphonate/quaternary ammonium; T: targeted; T/B: tumor-to-background ratio; T/Bl: tumor-to-blood ratio; TIONts: titanate nanotubes; T/L: tumor-to-lung ratio; T/Li: tumo to-liver ratio; T/M: tumor-to-muscle ratio; T/S: tumor-to-spleen





















































Fig. 7. Biodistribution and tumor uptake of radiolabeled targeted AuNPs, radiolabeled untargeted AuNPs or small radiolabeled monomers after IV administration. (A) After IV
administration, small radiolabeled monomers demonstrate a short blood circulation half-life and are rapidly excreted via glomerular filtration. This is in contrast to AuNPs larger than
5.5 nm, which are unable to pass through the glomerular filtration barrier. (B) Sagittal PET images of three rats acquired at various time points after IV injection of [64Cu]Cu-DOTA
[64Cu]Cu-DOTA-PEG2K or [64Cu]Cu-AuNS. (H, Heart; L, Liver; S, Spleen; K, Kidneys; T, Tumor). Color intensity scale is denoted as red > yellow > green > blue. The PET images show a
rapid kidney uptake and a weaker tumor accumulation of the monomeric [64Cu]Cu-DOTA and [64Cu]Cu-DOTA-PEG2K compared to [64Cu]Cu-AuNS, which demonstrate an increased
tumor accumulation 4 h post-injection and a tumor retention longer than 44 h. Reprinted from [103]1. (C) A major part of the targeted and untargeted radiolabeled AuNPs are typically
sequestrated by Kupffer cells in the liver, being part of the reticuloendothelial system (RES) and which can delay or inhibit the hepatobiliary excretion of the AuNPs. (D) Radiolabeled
AuNPs can accumulate in the tumor by the EPR effect and by active transendothelial transport pathways. There is a larger accumulation of targeted radiolabeled AuNPs in cancer cell
compared to untargeted radiolabeled AuNPs and radiolabeled monomers, thanks to their multivalent binding to cancer-specific receptors, which improves cancer cell binding and
uptake. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 1Fig. 7 B is reprinted from International Journal o
Pharmaceutics, Volume 395, Issues 1–2, H. Xie, Z. J. Wang, A. Bao, B. Goins and W. T. Phillips, In vivo PET imaging and biodistribution of radiolabeled gold nanoshells in rats with tumo
xenografts, Pages 324–30., Copyright (2010), with permission from Elsevier.
N. Daems, C. Michiels, S. Lucas et al. Nuclear Medicine and Biology 100–101 (2021) 61–90the phagocytic cells of the reticuloendothelial system (RES), which pre-
vents their efficient hepatobiliary elimination [108] (Fig. 7 B–C). Intraper-
itoneal (IP) administration of [99mTc]Tc-AuNP-RGD, [111In]In-AuNP@
Albumin and [67Ga]Ga-bombesin-AuNPs significantly reduces the nano-
particle sequestration by the RES, compared to IV administration




RGD is faster after IV injection (maximal after 1 h) than after IP adminis-
tration (maximal after 3 h). Furthermore, the [67Ga]Ga-bombesin-AuNPs
prostate tumor uptake is higher after IV injection, than after IP injection
[109]. Therefore, IV administration is probably more convenient for diag-
nostic purposes [51]. Alternatively, intratumoral (IT) injection delivers an
immediate high concentration of radiolabeled AuNPs inside the tumor,
N. Daems, C. Michiels, S. Lucas et al. Nuclear Medicine and Biology 100–101 (2021) 61–90while the AuNP concentration in healthy tissues is lower than after an IV
injection [110–114]. However, this administrationmethod is not common
for cancer detection.
Importantly, active targeting of AuNPs significantly improves the tu-
moral uptake compared to untargeted AuNPs (Fig. 7 D). However, cer-
tain targeting moieties can also increase the exposure of healthy
tissues to the radiolabeled AuNPs. For example, a high accumulation of
radiolabeled AuNPs is observed in the pancreas when the AuNPs are
conjugated to the peptides bombesin or octreotide [104,107,109,115].72Bombesin and octreotide target the gastrin-releasing peptide receptor
(GRP) and the somatostatin receptor, which are both highly expressed
in the pancreas, but are also overexpressed on prostate cancer cells
and neuroendocrine cancer cells, respectively. Orocio-Rodriguez, et al.
demonstrated a higher uptake of [99mTc]Tc-AuNPs-Tyr3-octreotide in
the pancreas compared to the monomeric [99mTc]Tc-Tyr3-octreotide
[107]. Furthermore, the pancreas-to-blood ratio of [99mTc]Tc-AuNP-
Lys3-bombesin was higher than that of monomeric [99mTc]Tc-Lys3-
bombesin [104]. Both observations were explained by the faster renal
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Another example is the higher liver and spleen uptake of AMD3100-
conjugated [64Cu]Cu‑gold nanoclusters (AuNCs) compared to
untargeted [64Cu]Cu-AuNCs. AMD3100 is an antagonist of the chemo-
kine receptor CXCR4, which is expressed on metastatic breast cancer
cells. However, CXCR4 is also present on immune cells residing in the
spleen and liver [68]. Similarly, conjugation of [111In]In-AuNPs to
Trastuzumab provokes a faster blood clearance and a higher uptake in
the liver and spleen of the nanoparticles compared to untargeted
[111In]In-AuNPs, which is explained partly by the Fc-mediated recogni-
tion and uptake of the [111In]In-AuNPs-Trastuzumab by the RES [110].
Despite the off-target uptake of these targeted, radiolabeled AuNPs,
the studies did not assess the toxic effects in the healthy organs.
3.1.2. Enhanced tumor uptake and retention
Despite the higher RES sequestration after IV injection, the average
tumor uptake of [99mTc]Tc-AuNPs-RGD (3.65% ID/g, glioma), [99mTc]
Tc-AuNPs-Tyr3-octreotide (≈3.4% ID/g, neuroendocrine tumor), [64Cu]
Cu-AuNCs-AMD3100 (7.15% ID/g, breast cancer), [64Cu]Cu-AuNS
(0.77% ID/g, squamous cell carcinoma) and [99mTc]Tc-resveratrol-
AuNPs (colon cancer) is considerably higher than that of [99mTc]Tc-
RGD (≈2.5% ID/g), [99mTc]Tc-Tyr3-octreotide (≈2% ID/g), [64Cu]Cu-
AMD3100 (2.98%ID/g), [64Cu]Cu-DOTA-PEG (0.09% ID/g) and [99mTc]
Tc-Resveratrol without AuNPs, respectively [51,102,103,107,116]
(Fig. 7 D). In addition, the early stage of 4T1 lung metastasis, which is
currently difficult to detect, is successfully imaged by[99mTc]Tc-AuNPs-
RGD (≈14% ID/g) and [64Cu]Cu-AuNCs-AMD3100 (7.36% ID/g),
whereas the small [99mTc]Tc-RGD and [64Cu]Cu-AMD3100 radiotracers
show a significantly lower uptake in these micro-metastatic lesions
(≈2.7% ID/g and 0.65% ID/g, respectively) [68,102] (Fig. 8 A-B). Impor-
tantly, the extent of tumor uptake of radiolabeled AuNPs depends on
the properties of the AuNPs, such as the size, the coating and the
shape. In size-comparing studies, the smaller radiolabeled AuNPs, in-
cluding 20 nm [111In]In-PEG-AuNPs, 29 nm Gd/[99mTc]Tc-AuNPs-RGD
and 30 nm [64Cu]Cu-DOTA-PEG-AuNPs, consistently exhibit a longer
blood circulation time, a higher tumor uptake and a lower RES seques-
tration compared to their larger counterparts (40 nm, 80 nm and
55 nm, respectively) (Fig. 8 C) [59,66,117]. Furthermore, a PEG coating
on [64Cu]Cu-AuNPs performs better in terms of a prolonged blood circu-
lation, a delayed RES sequestration and an increased uptake in a squa-
mous cell carcinoma compared to a zwitterionic coating or
stabilization by Tween 20 [69]. The functionalization and the length of
the PEG molecules have an influence on the stability and the in vivo be-
havior of the radiolabeledAuNPs. For instance, the immobilization of the
PEG molecules on the AuNP surface via thioctic acid or lipoic acid pro-
viding two or more gold‑sulfur bonds results in a higher stability and aFig. 8. Radiolabeled AuNP uptake in tumors andmetastatic lesions. (A) Quantitative uptake (in %
Cu-AuNCs-AMD3100 and [64Cu]Cu-AuNCs in themetastatic lesions of the lung of 4T1 tumor be
administration. * p< 0.05, ** p < 0.005, *** p< 0.001. T: tumor. M:metastasis. Adapted from [68
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AuNRs-Pt-RGD or [125I]I-AuNRs-Pt-RAD. Targeted [125I]I-AuNPs-Pt-RGD and [125I]I-AuNRs-Pt-
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is referred to the web version of this article.) 2Fig. 8 A is adapted with permission from ACS Na
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3Fig. 8 B is reprinted from Journal of Pharmaceutical Sciences, Vol. 104, Issue 8, P. M. Peiris, P. De
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73longer blood circulation time of 177Lu-labeled AuNPs and 111In-labeled
AuNPs compared to PEG immobilization via a single gold‑sulfur bond
[105,117]. In addition, longer PEG molecules (1000 and 5000 Da) pro-
longs the blood circulation time of PEG coated [64Cu]Cu-AuNCs and
[111In]In-AuNPs, compared to 350 and 2000 Da PEG molecules, respec-
tively [75,117]. However, increasing the length of the PEG molecules
from 800 to 6000 Da also reduces the breast cancer cell uptake of the
[111In]In-EGF-AuNPs [118]. In addition, Zhang, et al. demonstrated that
rod-shaped cisplatin (Pt)-loaded and 125I-labeled RGD-Pt-AuNRs ex-
hibit a longer blood circulation time, a more efficient targeting of the
lung tumor angiogenesis visualized by photoacoustic imaging and a
higher tumor accumulation, compared to the spherical [125I]I-AuNPs-
Pt-RGD with a similar size (Fig. 8 D-E) [99]. A longer blood half-life
might be attributed to a more efficient evasion of phagocytosis and
clearance by macrophages. As a result, the [125I]I-AuNRs-Pt-RGD have
more chance to permeate into the tumor than the [125I]I-AuNPs-Pt-
RGD [99].
Next to an increased tumor uptake, AuNPs increase the tumor reten-
tion of the radionuclide. For instance, the residence time of [177Lu]Lu-
Tyr3-octreotate-AuNPs in a 3D-multilayered culture of HeLa cells
(17.10 h) is significantly higher than that of monomeric [177Lu]Lu-
Tyr3-octreotate (5.13 h) [119]. Other studies confirmed the enhanced
tumor retention of AuNP-based radiopharmaceuticals in in vivo tumor-
bearing mice and rat models. In fact, [177Lu]Lu-AuNPs-RGD show a rat
glioma tumor residence time of 61.6 h after four IT injections, whereas
[177Lu]Lu-RGD remains in the tumor site for approximately 17.3 h [49]
. In addition, the accumulation of [64Cu]Cu-AuNS in the squamous cell
carcinoma achieves a plateau 20 h after IV injection. At 44 h after IV in-
jection, the majority of accumulated [64Cu]Cu-AuNS are still present in
the tumor, which is not the case for the monomeric [64Cu]Cu-DOTA-
PEG [103] (Fig. 7 B). Altogether, the enhanced tumor uptake and reten-
tion of targeted, radiolabeled AuNPs contribute to a high T/B ratio and
are mainly attributed to the EPR effect, the multivalent targeting avidity
and the high radionuclide cargo of the targeted, radiolabeled AuNPs,
compared to the small monomeric radiotracers (Fig. 7
D) [51,68,102,103,119].
3.1.3. Intratumoral distribution
Once within the tumor matrix, the most beneficial scenario is that
the radiolabeled AuNPs diffuse and spread uniformly throughout the
tumor tissue [7]. Several studies assessed the local intratumoral distri-
bution of the radiolabeled AuNPs using nuclear imaging, microscopic
examination or autoradiography.In the majority of the studies, AuNPs
are usually observed in the periphery of the tumormass close to the vas-
culature where they generally display heterogeneous distribution
[69,70,75,82,90,102,110,117,120–122]. The intratumoral diffusion ofID/g) and PET/CT transverse images show the accumulation of [64Cu]Cu-AMD3100, [64Cu
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charge and shape) and the tumor tissue (such as the cellular density
and the extracellular matrix stiffness) [123,124]. For instance, [198Au]
Au-nanospheres and [198Au]Au-nanodisks were found in the periphery
of a EMT-6 breast tumor, whereas [198Au]Au-nanorods and [198Au]Au-
nanocages were detected throughout, including the central region of
the tumor after IV injection [74]. Similarly, 30 nm [64Cu]Cu-DOTA-
PEG‑gold nanocages (AuNCages) accumulated in the central region of
the EMT-6 breast tumor 24 h after IV administration. The central74tumor accumulation of the [64Cu]Cu-DOTA-PEG-AuNCages is attributed
to the small size and neutral charge of the AuNPs as well as to the low
interstitial pressure and the uniform blood flow of the EMT-6 breast
cancer model, as visualized by photoacoustic imaging [59,74]. In addi-
tion, rod-shaped [125I]I-AuNRs-Pt-RGD penetrated much deeper into
the lung tumor interstitium than spherical [125I]I-AuNPs-Pt-RGD [99].
On the other hand, the heterogeneous distribution of Trastuzumab-
targeted and Cetuximab-targeted [111In]In-AuNPs in a breast tumor
and a squamous cell carcinoma, respectively, is partly attributed to the
N. Daems, C. Michiels, S. Lucas et al. Nuclear Medicine and Biology 100–101 (2021) 61–90‘binding-site barrier effect’. The binding-site barrier effect involves the
strong binding of the antibodies to their target, which facilitates the ex-
travasation of the AuNPs into the tumor, but also limits the intratumoral
diffusion of the AuNPs [110,120,125]. Finally, in an advanced solid
tumor with an aggressive tumor development, the presence of substan-
tial necrotic foci limits the delivery of AuNPs or other anti-cancer phar-
maceuticals [68]. Since [177Lu]Lu-AuNP-RGD significantly decrease
glioma progression and thus prevent the formation of necrotic foci,
[177Lu]Lu-AuNP-RGD display a more uniform intratumoral distribution
as compared to [177Lu]Lu-AuNPs or [177Lu]Lu-RGD [49].
Intratumoral penetration of radiolabeled AuNPs can also be pro-
moted by the application of external stimuli. For example, the uptake
of [64Cu]Cu-PEG-HAuNS-DOX in a squamous cell carcinoma in the
liver is enhancedwhen injection into the hepatic artery (i.e. liver embo-
lization) is followed by electroporation, radiofrequency ablation, or
laser-induced thermal therapy. Electroporation causes cell membrane
permeabilization via the use of electrical pulses, while radiofrequency
ablation and laser-induced thermal therapy both generate heat via the
delivery of an alternating electrical current and via laser irradiation, re-
spectively. As a result, the [64Cu]Cu-PEG-HAuNS-DOX are localized both
in and around the tumor, whereas embolization alone results in a pre-
dominant peripheral tumor uptake [58]. Another strategy is the co-
injection of an adjuvant such as lipiodol, which selectively enters liver
tumors after liver embolization. It boosts the uptake of [64Cu]Cu-PEG-
HAuNS throughout the tumor achieving a high tumor-to-normal liver
ratio of 4.17. Conversely, embolization of [64Cu]Cu-PEG-HAuNSwithout
lipiodol leads to a perivascular distribution and a lower tumor-to-nor-
mal liver ratio of 0.81 [126]. Similarly, IT co-injection of 103Pd/198Au-
dual radiolabeled AuNPs with the biocompatible polymer alginate se-
questrates them in prostate tumor [127].
3.2. Imaging
An early diagnosis of cancer is often related to a better prognosis.
Therefore, next to SPECT and PET imaging, the conventional, non-
invasive imaging systems, such as CT and MRI are essential in the clinic.
Gold nanoparticles have the potential to improve the contrast of CT im-
ages thanks to their high atomic number and high X-ray attenuation as
described in Section 1.3.2.
Besides CT imaging [128],MRI is also a common clinical imagingmo-
dality offering anatomical information in high-spatial resolution, with a
high contrast in soft tissue.MRI imaging is based on the relaxation of hy-
drogen protons and their electromagnetic energy emission after a radio-
frequency pulse, under the influence of a strong external magnetic field.
MRI contrast agents, T1-positive or T2-negative, affect the rate of the
proton relaxation and enhance the sensitivity and quality of the images
[129]. Thus, in order to exploit AuNPs as a contrast agent for MRI, they
need to be complexed with MRI contrast materials. For instance, multi-
component nanoparticles have been produced by surrounding a mag-
netic core of iron oxide with a gold shell, or by coupling iron-oxide
nanoparticles to AuNPs. Iron oxide is a superparamagnetic materialFig. 9. Image-guided therapy. (A) After IV injection of (targeted) radiolabeled AuNPs, nuclear im
treatment such as photothermal therapy. (B) PET/CT images acquired 24 h post-IV injection of
DAPTA) or untargeted Pd[64Cu]Cu@AuTripods-PEG in 4T1 tumor-bearing mice. The quantitati
Pd[64Cu]Cu@AuTripods-PEG-DAPTA after 24 h, which is higher compared to the tumor uptak
mice acquired 24 h post-IV injection of saline or Pd[64Cu]Cu@AuTripods-PEG-DAPTA and afte
cm2. (D) [18F]FDG PET/CT images of mice IV injected with Pd[64Cu]Cu@AuTripods-PEG-DAPTA
metabolic activity. B–D are adapted from [122]6. (E) Coronal PET images of U87MG tumor-be
untargeted [64Cu]Cu-AuNRs, showing a maximal tumor uptake of the targeted AuNRs after 2
tumor area. (F) Temperature mapping of tumor-bearing mice upon laser irradiation (808 nm,
RGD or without [64Cu]Cu-AuNRs-RGD. (G) Tumor growth curves of mice treated with or with
[72]7. 6Fig. 9 B-D are adaptedwith permission from ACS Nano, Vol. 10 Issue 3, B. Pang, Y. Zhao, H
tifunctional Nanomaterial for Positron Emission Tomography and Image-Guided Photothermal C
are adapted with permission from ACS Nano, Vol. 8 Issue 8, X. Sun, X. Huang, X. Yan, Y. Wang,
emission tomography imaging guided photothermal cancer therapy, Pages 8438–46, https://pu
sions related to the material excerpted should be directed to the ACS.
75exhibiting a strong magnetization under the influence of an external
magnetic field, creating microscopic field heterogeneity. This acceler-
ates the dephasing of the proton spins or the T2 relaxation process. As
a result, IV injection of these multicomponent NPs in tumor-bearing
mice significantly decreases the signal intensity in the tumors using
T2-weighted MRI (Fig. 10 D) [17,130–132]. On the other hand, coupling
AuNPs to paramagneticmetals, such as gadoliniumormanganese, accel-
erates the T1-relaxation process. As a result, administration of these
nanomaterials increases the signal intensity in the murine tumors, cre-
ating bright T1-weighted images (Fig. 10 A) [133–138].
Combination ofmultiple imagingmodalities, such as PET or SPECT im-
aging with MRI or CT imaging improves the diagnostic accuracy by
merging the high spatial resolution and precise anatomical detail pro-
vided by CT and MRI with the high sensitivity and the unique functional
information of nuclear imaging [112,139–141]. Furthermore, multimodal
nuclear imaging using radiolabeled AuNPs has also been used to perform
image-guided, AuNPs-mediated PTT (Fig. 9 A-G) and enhanced
external beam radiotherapy (EBRT) (Fig. 10 A-C) [66,72,122,142].
Table 2 provides an overview of the pre-clinical studies assessing the
ability of radiolabeled AuNPs to improve or to combine multiple nuclear
imaging modalities.
3.2.1. Multimodal imaging
The radiolabeling of AuNPs enables the improvement of PET-CT and
SPECT-CT. For instance, targeted dendrimer-entrapped AuNPs and
polyethylenimine-entrapped AuNPs, radiolabeled with technetium-
99m or with iodine-131, enhance the CT contrast on one hand and en-
able SPECT imaging on the other hand of sentinel lymph nodes as well
as of glioma cells,fibrosarcoma cells, cervical cancer cells and hepatocel-
lular carcinoma cellscells. The X-ray attenuation property of the AuNPs
is exceeding that of Omnipaque, a clinically used iodine-based CT
contrast agent [63,81,144–147,151]. Furthermore, the increase in
SPECT(-CT) signal intensity is related to the concentration of gold and
the radionuclide in the tumor cells. As a result, the SPECT(-CT) imaging
contrast enhancement significantly improves when cancer targeting
probes, such as chlorotoxin, chlorotoxin-like peptides, duramycin,
cRGD, EGF, folic acid or pH-responsive moieties are linked to the
nanocarriers as compared to the untargeted analogues, negative cancer
cell models or blocked cancer cell receptors (Fig. 8 D-E and Fig. 10
B) [51,62,65,66,81,91,92,118,143–145,147,151,152]. Similarly, the PET(-
CT) imaging signal after IV injection of targeted RGD-[64Cu]Cu-AuNR,
[64Cu]Cu-AuNCs-AMD3100, Pd[64Cu]Cu@AuTripods-PEG-DAPTA, [64Cu]
Cu-AuNS-RGDfK and [64Cu]Cu-AuNCages-PEG-MSH in glioblastoma,
breast cancer, squamous cell carcinoma and melanoma is higher than
after IV injection of the untargeted [64Cu]Cu-AuNR, [64Cu]Cu-AuNCs, Pd
[64Cu]Cu@AuTripods-PEG, [64Cu]Cu-AuNS and [64Cu]Cu-AuNCages-PEG,
respectively (Fig. 9 B; 9 E) [68,72,122,142,149]. Furthermore, PET imaging
enables image-based photothermal therapy. Indeed, PET images showed
a maximal uptake of RGD-[64Cu]Cu-AuNR and Pd[64Cu]Cu@AuTripods-
PEG-DAPTA in a glioblastoma and breast tumor after 24 h, respectively,
whichwas followed by photothermal therapy using 808 nm laser irradia-aging can be used to determine themaximal uptake of theAuNPs in the tumor site to start a
CCR5-targeting, DAPTA-conjugated 64Cu-doped AuTripods (Pd[64Cu]Cu@AuTripods-PEG
ve tumor uptake at 1 h, 4 h and 24 h post-IV injection shows a maximal tumor uptake o
e of Pd[64Cu]Cu@AuTripods-PEG. T, tumor; L, liver. (C) Thermographs of tumor-bearing
r laser irradiation of the tumor for 0, 1, 3 or 10 min. The laser power density was 1.2 W
or saline and acquired 24 h after photothermal therapy demonstrating a reduced tumo
aring mice aqcuired 4 h, 16 h, 24 h, and 45 h after IV injection of [64Cu]Cu-AuNRs-RGD o
4 h, which is higher than the tumor uptake of the untargeted [64Cu]Cu-AuNRs. Arrow =
1 W cm−2) for 1, 3, and 10 min, acquired 24 h after IV administration of [64Cu]Cu-AuNRs
out [64Cu]Cu-AuNRs-RGD and in combination with laser irradiation. E-G are adapted from
. Luehmann, X. Yang, L. Detering, M. You, et al. (6)(4)Cu-Doped PdCu@Au Tripods: A Mul
ancer Treatment, Pages 3121–31, Copyright (2016) American Chemical Society. 7Fig. 9 E-G
J. Guo, O. Jacobson, et al. Chelator-free (64)Cu-integrated gold nanomaterials for positron
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ity (Fig. 9 A-G) [72,122].
Yang, et al., combined SPECT-CT and high-resolution MRI by conju-
gating 29 nm, 51 nm and 80 nm cRGD-AuNPs to technetium-99m and
gadolinium (Fig. 10 A-C). From the three different AuNP sizes that
were investigated, the 29 nm-sizedAuNPs showed the greatest accumu-
lation in the non-small-cell lung xenograft in mice. The authors found
hyper-intense MRI signals in the tumor region, 30min post-IV injection
of 29 nmTc/Gd-cRGD-AuNPs, after which theMRI signal intensity grad-
ually increased to values that were 2.4 times higher than the baseline
signal, reaching a plateau 2 h after injection. In addition, the MRI signal
enhancement is much less pronounced in mice that received the
untargeted Tc/Gd-AuNPs probes or free cRGD, which block the tumor
binding sites (Fig. 10 A). The SPECT-CT images confirm theMRI observa-
tion, demonstrating high tumor accumulation of 29 nm [99mTc]Tc/Gd-
cRGD-AuNPs (14.6% ID/g) after 2 h, which strongly reduces after
blocking (6.2% ID/g) or after administration of the untargeted [99mTc]
Tc/Gd-AuNPs probe (4.0% ID/g) (Fig. 10 B). However, SPECT-CT also re-
veals that the [99mTc]Tc/Gd-cRGD-AuNPs are present in the liver (≈20%
ID/g) and spleen (≈55% ID/g). Furthermore, ex vivo studies demonstrate
a high 99mTc-content in the urine (>60% ID/g), while the amount of gold
in the urinewas low (≈10% ID/g), which demonstrates the detachment
of technetium-99m from the AuNPs. Due to the size limitations during
glomerular filtration, the presence of gold in the urine from the rela-
tively large sized 29 nm, 51 nm and 80 nm AuNPs may be an indication
of temporary kidney damage [153]. However, the authors did not ob-
serve any lesions, inflammation or other histological abnormalities in
the kidneys. The [99mTc]Tc/Gd-cRGD-AuNPs are potentially suitable for
image-based therapy as the authors were able to define the optimal
time point post-injection at which the AuNP content in the tumor site
was maximal to perform EBRT and benefit from the AuNP
radiosensitization effect (Fig. 10 C) [66]. Alternatively, a targeted PET/
MRI imaging probe was created by developing a multicomponent sys-
tem consisting out of (I) AuNPs, which were radiolabeled with copper-
64, and (II) iron-oxide nanoparticles (IONPs), which acted as MRI re-
porters and were conjugated to anti-EGFR affibodies (Fig. 10 D-E). The
Au-IONPs show a similar T2 relaxation rate of water as Feridex, a colloi-
dal superparamagnetic iron oxide MRI contrast agent, and reduces the
MR signal intensity at the tumor site by 44%on T2-weightedMRI images,
48 h after IV injection in squamous cell carcinoma-bearingmice (Fig. 10
D). Next to RES accumulation, the PET images shows high tumor uptake
(4.6% ID/g, 24 h p.i.) and a good tumor-to-muscle ratio of approximately
6 (Fig. 10 E). Blocking the tumor binding sites reduces the tumor uptake
(1.9% ID/g, 24 h p.i.), resulting in a tumor-to-muscle ratio of approxi-
mately 2 and abolishes the effect on the MRI and PET signal intensity
in the tumor region (Fig. 10 D-E) [132].
Another multimodal imaging possibility was demonstrated by cou-
pling and embedding the positron-emitting iodine-124 in PEGylatedFig. 10.Multimodal imaging. (A) T1-weightedMR imagingofH1299 tumor-bearingmice at diffe
AuNPs-RAD (RAD) or Gd/Tc-AuNPs-RGD plus free RGD peptide (COM). Gd/Tc-AuNPs-RGD sh
blocking with free RGD. (B) SPECT/CT imaging of H1299 tumor-bearing mice at different time
RAD, or Gd/[99mTc]Tc-AuNPs-RGD plus free RGD peptide. Gd/[99mTc]Tc-AuNPs-RGD show an
blocking with free RGD. (C) Tumor growth curves following different treatment modes. Mice
plus free RGD peptide at a dose of 2.5 mmol of Au/kg. Radiotherapy with 10 Gy of γ-ray irrad
RGD enhance tumor radiotherapy. A-C are adapted from [66]8. (D) in vivo T2-weighted MR im
Cu-NOTA-Au-IONP-Affibody and of a blocking dose of Affibody. (E) Coronal PET images of A4
Au-IONP-Affibody and the blocking dose of Affibody. [64Cu]Cu-NOTA-Au-IONP-Affibody show
axial PET/CT images show uptake of [124I]I-Au@AuCBs-PEG in breast cancer lesions of tumo
lesions, respectively. Ex vivo PET image of an excised tumor. (G) Photographs with CLI images
24 h after IV injection. Ex vivo CLI image of an excised tumor. F-G are adapted from [90]10. (F
the web version of this article.) 8Fig. 10 A-C are adapted with permission from ACS Appl Ma
Angiogenesis Targeted Radiosensitization Therapy Using Gold Nanoprobes Guided by MRI/SP
are reprinted from Biomaterials, Vol. 34 Issue 11, M. Yang, K. Cheng, S. Qi, H. Liu, Y. Jiang, H. J
tumor PET, optical and MR imaging, Pages 2796–806, Copyright (2013), with permission from
Kim, et al., PEGylated crushed gold shell-radiolabeled core nanoballs for in vivo tumor im
Nanobiotechnology, Vol. 16 Issue 1, https://jnanobiotechnology.biomedcentral.com/articles/10
Commons BY 4.0 license (https://creativecommons.org/licenses/by/4.0/). Copyright (2018) Th
77gold core nanoballs (AuCBs) ([124I]I-Au@AuCBs-PEG), which allowed
in vivo PET-CT scanning and optical Cerenkov luminescence imaging
(CLI). CLI is based on the detection of Cerenkov photons, which arise
from charged particles originating from the radionuclide decay and
traveling through a dielectric medium with a velocity exceeding the
speed of light in the given medium. Particle deceleration polarizes the
electrons of water molecules, which relax back to the equilibrium by
emittingphotons [154]. CLI can compensate for the relatively low spatial
resolution of PET imaging, while PET overcomes the penetration depth
limitation of the optical CLI imaging. Furthermore, CLI provides the op-
portunity to utilize existing clinical radiotracers for image-guided sur-
gery. Despite the significant uptake in the liver and spleen, the PET-CT
imaging shows a rapid accumulation of [124I]I-Au@AuCBs-PEG in a xe-
nograft breast tumor lesion as early as 1 h post-IV injection in mice
(5.38% ID/g). Thereafter, the signal decreases, but remains detectable
at 24 h post-injection (1.81% ID/g) with a desirable tumor-to-muscle
(T/M) ratio of approximately 5 (Fig. 10 F). The authors do not demon-
strate early time point evaluations of CLI imaging (1 h). However, con-
sistent with the PET-CT results, in vivo CLI imaging also visualizes the
uptake of the [124I]I- Au@AuCBs-PEG in the tumor at 24 h post-
injection (Fig. 10 G). As a result, there is a good linearity between the
PET-CT and CLI imaging at 24 h (R2 = 0.85) [90].
In addition, PET-CLI imaging is useful to detect sentinel lymph nodes
(SLNs) after subcutaneous injection of [124I]I –AuNP-PEG. SLNs are the
first lymph nodes to which cancer cells of the primary tumor are likely
to spread. Therefore, detection of the SLNs are required in order to de-
termine the clinical cancer stage. The PET-CLI images show [124I]I-
AuNP-PEG uptake in the SLNs as early as 1 h post-injection (≈30% ID/
g). The signal intensity increases to a maximum after 6 h and remains
evident after 24 h (≈10% ID/g) [78]. As a result, PET/CLI could facilitate
the clinical staging of cancer. Similarly, SLNs are also successfully imaged
using SPECT-CT at 0.5 h, 1 h, 4 h and/or 24h after subcutaneous injection
of 99mTc-labeled polymer-entrapped AuNPs and [99mTc]Tc-AuNP-man-
nose [52,63,146]. Conjugation of the AuNPs with mannose helps to im-
prove the uptake of the [99mTc]Tc-AuNPs, since it targets the lymph
node macrophages [52].
3.2.2. Dual radiolabeling
Alternative tomultimodal imaging, dual radiolabeling of AuNPswith
indium-111 and iodine-125 enables multispectral SPECT imaging, in
which the emissions from iodine-125 and indium-111 are indepen-
dently tracked at a window centered around 28 keV and 200 keV, re-
spectively. Multispectral imaging helps to study the radiolabeling
stability, the radionuclide anchor stability and biological parameters,
such as enzyme activity. For example, indium-111 and iodine-125 are
specifically linked to a matrix metallopeptidase 9 (MMP9) -cleavable
peptide, which in turn is conjugated to the AuNPs. Indium-111 and
iodine-125 are separated from each other by the cleaving sequence,rent time points after IV injectionwith 29nmGd/Tc-AuNPs-RGD (RGD), untargeted Gd/Tc
ow an increased tumor uptake compared to the untargeted Gd/Tc-AuNPs-RAD and afte
points after IV injection with Gd/[99mTc]Tc-AuNPs-RGD, untargeted Gd/[99mTc]Tc-AuNPs
increased tumor uptake compared to the untargeted Gd/[99mTc]Tc-AuNPs-RAD and afte
were IV injected with 29 nm Gd/Tc-AuNPs-RGD, Gd/Tc-AuNPs-RAD or Gd/Tc-AuNPs-RGD
iation was performed 4 h post-IV injection. Control groups received PBS. Gd/Tc-AuNPs
ages of A431 tumor-bearing mice acquired before and at 48 h after IV injection of [64Cu
31 tumor-bearing mice acquired 4 h, 24 h and 48 h after IV injection of [64Cu]Cu-NOTA
excellent and specific tumor imaging ability. D-E are reprinted from [132]9. (F) 3D and
r-bearing mice after IV injection. White and yellow circles indicate muscle and tumo
showing uptake of [124I]I-Au@AuCBs-PEG in breast cancer lesions of tumor-bearing mice
or interpretation of the references to colour in this figure legend, the reader is referred to
ter Interfaces, Vol. 8 Issue 3, Y. Yang, L. Zhang, J. Cai, X. Li, D. Cheng, H. Su, et al., Tumo
ECT Imaging, Pages 1718–32, Copyright (2016) American Chemical Society. 9Fig. 10 D-E
iang, et al., Affibody modified and radiolabeled gold‑iron oxide hetero-nanostructures fo
Elsevier. 10Fig. 10 F-G are adapted from S. B. Lee, D. Kumar, Y. Li, I. K. Lee, S. J. Cho, S. K
aging with dual positron emission tomography and Cerenkov luminescent imaging,
.1186/s12951-018-0366-x. Open access article distributed under the terms of the Creative
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leased, while iodine-125 should remain attached to the AuNP. However,
4 h after IV injection in tumor-bearing mice, iodine-125 is detected in
the thyroid, stomach and bladder, indicating that radioiodination of
the tyrosine residue in the peptide is lacking in vivo stability, whereas
indium-111 remains chelated to the AuNPs, circulating in the blood
pool. Tumor uptake was clearly visible 24 h post-injection in both
MMP9-high expressing A431 squamous cell carcinoma and MMP9-
low expressing 4T1Luc breast cancer due to the EPR effect, leading to a
high T/M ratio of 8, after 48 h. However, due to the high MMP9 enzyme
activity in the A431 tumor, the 111In-labeled peptide is cleaved from the
AuNPs, facilitating its tissue clearance and potentially its kidney excre-
tion. As a result, the 111In-signal intensity in the MMP9-high A431
tumor reduces between 24 h and 48 h (from 7.25 to 6.23% ID/g). In con-
trast, the signal intensity in the MMP9-low 4T1Luc tumor continues to
increase (from 6.41 to 10.2% ID/g), indicating a low MMP9 enzyme ac-
tivity [82]. Dual radiolabeling is also useful to establish the
biodistribution of multi-component AuNPs. This was proven by IV ad-
ministration of [198Au]AuNPs with a [14C]C-citrate surface coating to
rats. Gamma spectrometry and liquid scintigraphy were used to detect
and quantify the gold-198 and carbon-14 activity in the ex vivo organs,
respectively. Interestingly, the biodistribution profile of the gold core
and the citrate coating were different from each other and thus the au-
thors concluded that the different components of the AuNPs separated
one from each other and that the AuNPs did not remain intact [155].
3.3. Treatment
For therapeutic purposes, the goal of radiolabeled AuNPs is to deliver
a lethal radiation dose to the tumor site, while minimizing the radiation
damage to healthy tissue. The effectiveness of radiolabeled AuNPs for
TRT and as multimodal therapeutic agents has been investigated
in vitro and in vivo. These studies are presented in detail in Table 3.
3.3.1. In vitro experiments
Radiolabeled AuNPs can potentially increase the effectiveness of TRT.
For instance, in vitro, AuNPs conjugated to Lys3-bombesin (Tat-BN) and
radiolabeledwith technetium-99m are stronger inhibitors prostate can-
cer cell (PC-3) proliferation (cell proliferation of <10%) than the mono-
meric [99mTc]Tc-Tat-BN without AuNPs (cell proliferation of ≈37%).
Furthermore, the research group demonstrated an enhanced PC-3 cyto-
toxic effect of dual-radiolabeled [99mTc]Tc/[177Lu]Lu-AuNP-Tat-Bn as
compared to the single radiolabeled [177Lu]Lu-AuNP-Tat-BN or [99mTc]
Tc-AuNP-Tat-BN, which is attributed to the biological effects of Auger
electrons and low-energy internal conversion of technetium-99m [50].
In line with the results of [99mTc]Tc-Tat-BN, the [177Lu]Lu-AuNPs-RGD
inhibited glioma cell (C6) proliferation (cell proliferation of 3.62%) sig-
nificantlymore as compared to themonomeric [177Lu]Lu-RGD (cell pro-
liferation of 29.67%) without AuNPs [49].
The combination of TRT with photothermal therapy was studied
in vitro, showing radiotoxicity of [99mTc]Tc/[177Lu]Lu-AuNP-Tat-BN
and dendrimer-entrapped [177Lu]Lu-AuNP conjugated to folate and
bombesin ([177Lu]Lu-DenAuNPs-folate-bombesin) in prostate cancer
cells and breast cancer cells, while the corresponding unlabeled analogs,
DenAuNP-folate-bombesin and AuNPs-Tat-BN, exhibit thermo-ablative
properties following laser irradiation at 532 nm for 6 min (0.65 W/
cm2). It is important to note that laser irradiation at 532 nm, close to
the SPR peaks of the respective AuNPs, has a limited clinical application,
due to its poor tissue penetration [50,158]. Nevertheless, the studies
highlight a proof-of-principle for future research on the TRT/
photothermal combination therapy.
Various in vitro studies demonstrate that the conjugation of
targeting ligands directed against EGFR1 (Cetuximab or EGF) or
EGFR2 (Trastuzumab or Panitumumab) increases the effectiveness
of AuNPs, radiolabeled with iodine-131, indium-111, lutetium-177,
gold-198 or astatine-211, to reduce the viability of EGFR1- or78EGFR2-expressing cancer cells, respectively [60,61,84,95,156,159]. First,
[111In]In-AuNPs-Trastuzumab, [177Lu]Lu-AuNP-Panitumumab, [177Lu]Lu-
AuNPs-Trastuzumab and [211At]At-AuNP-PEG-Trastuzumab show a
higher cytotoxic effect than their untargeted, radiolabeled AuNPs analogs
[61,95,156,159]. Second, increasing the EGF load on [111In]In-EGF-AuNPs
increases its cytotoxic efficacy [60]. Third, cancer cells with a low or inter-
mediate HER1/HER2 expression profile are less affected by the targeted
radiopharmaceuticals as compared to the cells with a high receptor ex-
pression [60,61,156,159]. Finally, pre-blocking the binding sites on A549
lung cancer cells diminishes the cytotoxic effect of [131I]I-Cetuximab-
AuNPs [84].
3.3.2. Intravenous injection in tumor-bearing mice
There are a limited number of in vivo studies, which intravenously in-
ject radiolabeled AuNPs to investigate their use as potential agents for
TRT. For instance, IV administration of 7 doses of polyethylenimine-
entrapped AuNPs, radiolabeled to iodine-131 and conjugated to
chlorotoxin ([131I]I-Au PENPs-BmK CTX and [131I]I-Au PENPs-CTX) in
glioma-bearing mice over a period of 3 weeks significantly slows down
the tumor growth and prolongs the survival as compared to the saline
control, the untargeted AuNP analogs or the non-radioactive AuNP ana-
logs [81,151]. In addition, a single IV injection with three different doses
of [198Au]AuNPs-RGD, 18.5 MBq, 37 MBq and 55.5 MBq, in melanoma-
bearing mice significantly retarded the tumor growth. More specifically,
the tumor growth retardation enhances as thedose increased,with amin-
imal tumor growth delay using 18.5 MBq and with tumor regression
using doses of 37–55.5 MBq. However, the body weight of the mice
treatedwith 55.5MB of [198Au]AuNPs-RGD reduced by 10–15% over a pe-
riod of 15 days, potentially due to radiotoxicity [164]. Next to the delivery
of radionuclides to the tumor site, radiolabeled AuNPs can also act as
radiosensitizers. This was investigated in vivo, where SPECT-CT imaging
was used to define themaximal tumor delivery of iodine-125 after IV ad-
ministration of [125I]I-cRGD-AuNPs in small cell lung cancer-bearingmice,
which was then followed by EBRT. Combined [125I]I-cRGD-AuNPs and
EBRT suppress the tumor growthmore effectively during 21 days as com-
pared to no treatment, EBRT alone, AuNPs+EBRT and cRGD-AuNPs
+EBRT.However, there is no significant difference in the apoptotic degree
caused by [125I]I-cRGD-AuNPs and cRGD-AuNPs, 2 days after EBRT. The
authors suggested that a significant increase in therapeutic efficacy
might be possible if iodine-125 is exchanged by iodine-131, which has a
higher therapeutic potency [83].
3.3.3. Nanobrachytherapy: the Intratumoral injection of radiolabeled
AuNPs in tumor xenografts
Themajority of the research assessing the effectiveness of radionuclide
therapy using radiolabeled AuNPs in vivo chose for an intratumoral route
of administration, usuallywith the aim to improve the therapy of localized
prostate cancer or breast cancer [49,105,127,156,159–163,165]. As men-
tioned before, studies comparing the biodistribution of radiolabeled
AuNPs after IT administration and IV administration demonstrate that
intratumoral administration maximizes the tumor concentration of the
radiolabeled AuNPs and minimizes the accumulation in healthy tissue,
such as the liver and spleen, compared to IV injection [110–114,156].
Furthermore, the intratumoral administration strategy of radiolabeled
AuNPs is suggested as a potential alternative for the implantation of con-
ventional radioactive seeds during interstitial brachytherapy, called
nanobrachytherapy (Fig. 11) [127,165,167]. Interstitial brachytherapy is
based on the implantation of millimeter-sized radioactive seeds in or
near the tumor, providing a continuous dose delivery. The implantation
of the radioactive seeds is often permanent for the treatment of prostate
cancer. Although successful, there are certain limitations associated to
thismode of therapy. For instance, the implantationprocedure using cath-
eters is invasive, causes bleeding anddiscomfort, andhas an increased risk
on trauma, edema, urinary obstruction and pain during urination. In addi-
tion, since each seed typically has an activity ranging between 18.5‐ and
74 MBq, the intratumoral dose distribution in the prostate gland is
Table 3
Overview of radiolabeled gold nanoparticles under pre-clinical investigation for their therapeutic potentials.
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%CS: [131I]I-C 5-AuNPs: 37 (2 h)
%CS after bloc ng: >82.
T/M: 3.9 (2 h – 5.5 (4 h)
Kao, et al. [84]
[131I]I-Au PENP-BmK CTX 147 Chlorotoxin-like
peptide (T)
Untargeted (UT)
Covalent C6, rat glioma,
IV





Tumor volum increased 17-22× (controls), 20× (UT)
and 7× (T) af r 3 weeks. Treatment with T results in
prolonged su ival compared to UT. Higher tumor
SPECT (2×) a CT (1.67×) signal intensities compared
to UT-form, 6 h p.i.
Sun, et al. [81]
[131I]I-Au PENPs-CTX 151 Chlorotoxin (T)
Untargeted (UT)
Covalent C6, rat glioma,
IV





Treatment wi T leads to higher tumor SPECT
(2.2–2.4×) an CT (1.7×) signal intensities compared
to treatment ith UT, 6-8 h p.i. Tumor volume
increased 18. (UT), 9.7× (T) and 19.6–21.9×
(controls). Su ival time after treatment with T was
significantly l ger than after treatment with UT.
Zhao, et al. [151]






TRT and PTT Cellular uptak after 24 h: barely uptake of Na[131I]I
and 32.1% of 1I]I(0)-AuNRs.
Cell viability er radionuclide therapy and PTT:
- 6 μCi: Na[13 I: no therapeutic effect vs. [131I]I
(0)-AuNRs: 7 96%
- PTT: [131I]I( -AuNRs: 60.81%
- 6 μCi + PTT [131I]I(0)-AuNRs: 31.09%
More effectiv umor growth inhibition by [131I]I
(0)-AuNRs-PE than free iodine-131. Combining TRT
and PTT leads o tumor regression.
Wang, et al. [97]




37 MBq, 100 μl
In vivo RT and TRT.
SPECT-CT
T/NT tumor u ake ratio: 2.07 (1 h) - 4.76 (2 h) - 4.25
(4 h).
T/NT apoptos ratio (2 days after RT): RT+[125I]
I-cRGD-AuNP 11.2| RT + cRGD-AuNPs: 9.8| RT
+ AuNPs: 5.5 RT alone: ≈5 | no treatment: ≈3%
increase in tu or vol. (grams) (after 21d): Control:
312 (0.538) | : 137 (0.209) |RT + AuNPs: 85.5
(0.171)| RT+ GD-AuNPs: 33.1 (0.113) | RT+[125I]
I-cRGD-AuNP 15.2 (0.116) ➔Therapeutic effect of
[125I]I- cRGD- NPs+RT not significantly improved
compared to GD-AuNPs+RT.
Su, et al. [83]
Indium-111 [111In]In-EGF-Au NPs 14 EGF Chelation MDA-MB-468,
MCF-7, human
breast cancer
In vitro TRT SF MDA-MB-4 3: 42.8%. Increasing the EGF loading on
the AuNP, red ces the SF to 17.1%. Not toxic to MCF-7
Song, et al. [60]











TRT T form was in rnalized more efficiently in the
perinuclear re ion, lead to more DSBs and cell death in
both cell type than the UT form. The uptake and cell
death is highe in SK-BR-3 cells than in MDA-MB-361
cells treated w th T form.
T form arrest tumor growth over 70 days.
Control: 8× tu or volume increase over 70 days
Absorbed dos T: 60.5 Gy – UT: 28.4 Gy (48 h)





Chelation C6, rat glioma




Inhibited C6 c l proliferation (3.6%) compared to UT
form (6.3%) a [177Lu]Lu-cRGD (29.7%).
% ID/g (T): 68 (3 h) - 34.7 (96 h) | SUV18F-FDG: 0.335
(23d)














































































Purpose Therapeutic e ct Reference
% ID/g ([177Lu u-cRGD): 26.8 (3 h) - 5.7 (96 h) |
SUV18F-FDG: 2 0 (23d)
Absorbed dos T: 63.8 Gy - UT: 38.3 Gy - [177Lu]
Lu-RGD: 16.6 y (23d)
T treatment: mor size was 27× smaller than control,













In vitro TRT in vitro %CS (high) T: 1.7 (1.5 MBq) - 0.1 (3 MBq) - <0.001
(4.5 MBq)
%CS (high) UT 43.1 (1.5 MBq) - 22.5 (3 MBq) - 8.4
(4.5 MBq)
%CS (mod) T: 8.1 (1.5 MBq) - 46.4 (3 MBq) - 33.8
(4.5 MBq)
%CS (mod) U 84.2 (1.5 MBq) - 64.8 (3 MBq) - 51.6
(4.5 MBq)
%CS (low) T: .1 (1.5 MBq) - 30.3 (3 MBq) - 25.8
(4.5 MBq)
%CS (low) UT 4.3 (1.5 MBq) - 31.9 (3 MBq) - 32.3
(4.5 MBq)












% ID/g (T): 46 7 (1 h) and 196.6 (48 h)
% ID/g (UT): 3 1.1 (1 h) and 99.0 (48 h)
TGI of T was 3 × lower (0.3) than TGI of control (11.1)
(90d). No diff ence in TGI of T (0.3) and UT form
(0.8). Mice tr ted with T and UT survived for 120d.
Controls surv ed for 75-86d. Absorbed dose: T:
30.37 Gy - UT 21.86 (48 h)
Yook, et al. [157]
[177Lu]
Lu-DenAuNPs-folate-bombesin








Absorbed dos T: 15.1 Gy – UT: 63.2 Gy (72 h,
14.8 Bq/cell)













In vivo TRT in vitro
and in vivo
T form was in rnalized more in BT-474 and SK-BR-3
cells than in M A-MB-361 cells. The T form was
internalized a d retained more efficiently than the UT
form in SK-BR cells, and lead to more DSBs and cell
death.
TGI after 16 d s: (T) = 2.5 | (UT) = 4.2 | (saline)
= 5.6










In vitro PTT and TRT
in vitro
52% more int nalization than UT form. Significantly










3 weeks after eatment, tumor volume of treated
group was 82 smaller (0.17 cm3) as compared to the
control group 0.86 cm3). After 31 days: % ID: 19.9
Chanda, et al.
[160]
[198Au]AuNPs-EGCg 80 epigallocatechin-gallate Incorporation PC-3, human
prostate cancer
IT, 5 MBq, 30 μl
In vivo Radionuclide
therapy
72% tumor re ntion (24 h) - % ID: 37.4 (42d)
80% tumor vo me reduction after 28 d (reduced by
0.28 cm3) com ared to controls (reduced by 0.05 cm3)
Shukla, et al.
[161]








% ID: 53 (30 m n). Tumor volume was stable (n = 6)
or reduced by 0–50% (n = 2). One dog had a tumor
volume incre e of 26%.
Axiak-Bechtel,
et al. [162]
[198Au]AuNPs-MGF 35 Mangiferin Incorporation PC-3, human
prostate cancer
IT, 6 MBq, 30 μl
In vivo Radionuclide
therapy
% ID: 80.98 (0 h) - 79.82 (24 h) – 60.96-69.7 (24d)






























































Tumor volume control group: 1.31 cm3 (6.5×
increase) (24







% ID/g: 4.9–8 - 7.6 - 6.6 - 5.1 (1 h - 4 h - 24 h -72 h -
168 h)
% ID/g (block ): 2.9 (4 h) - % ID/g (UT): 3 (4 h)
T/M: 9.6–29.8 1 h - 168 h)
T/Bl: 1.4–10 ( h - 168 h)
T/Li: 0.19–1.2 1 h - 168 h)
Tumor growt retarded in treated mice compared to
saline or AuN RGD. The growth deceleration
enhanced wit increasing dose. Mice treated with
37.0–55.5 MB reduced in TGI. No change in body
weight of mic treated with 18.5–37.0 MBq. There was
















After 4 weeks Control group reached endpoint
Tumor volum of treated group 1 were 56% smaller
Tumor volum of treated group 2 were 75% smaller,
but severe sk necrosis.










% ID/g: 101.5 4 h) – 274.5 (5w)
Tumor contro m3: ([103Pd]Pd@Au): 82.7 to 19.8
(5w) Metabo activity decreased with 62% (5w)
Tumor contro m3: (PBS): 67.1 to 187, (cold Au):
58.7 to 122 (5 )
Moeendarbari,
et al. [165]
Actinium-225 [225Ac]Ac-Au@TADOTAGA 5–9 N.A. Chelation U87MG, human
glioblastoma,
IT, 3 × 5 kBq,
100 μl
In vivo TRT in vivo % IA/g: 60.67% 2 h) - 5.21% (228 h).
TGI of treated ice was 2.4-fold lower at 8 days and












In vitro TRT LD50 (T): 0.55 Bq/ml (24 h)
LD50 (UT): 1.3 Bq/ ml (24 h)
Bioconjugate uccessfully penetrate SKOV-3 cells and










In vitro TRT metabolic act ity: non-radiolabeled AuNP-S-PEG-SP
(5–11): 88% ( h)
metab. Act.: U : ≈55% (24 h)
metab. Act.: T ≈38% (24 h)
Dziawer, et al.
[94]
Abbreviations: AuNP: gold nanoparticle; Au-PENPs: polyethylenimine-entrapped gold nanoparticles; BmK-CTX: Buthusmartensii Karsch chlorotoxin; CT: computed tomography; D AuNPs: dendrimer conjugated gold nanoparticles; DSBs: double
strandbreaks; EGCg: epigallocatechin-gallate; EGF: epidermal growth factor receptor; FDG:fluorodeoxyglucose; GA: gumarabic; IT: intratumoral; IV: intravenous; LACT: Lactobacillus amnosus; LD50: lethal dose for 50% of the cells;MGF:mangiferin;
PEG: polyethylene glycol; p.i.: post-injection; PTT: photothermal therapy; RT: radiotherapy; SF: survival fraction; SPECT: single photon emission computed tomography; SP(5–11): ubstance P(5–11); SUV: standardized uptake value; T: targeted;
TAT-Bn: TAT-bombesin; TGI: tumor growth index (ratio of the treated tumor volume by the initial tumor volume); T/M: tumor-to-muscle ratio; T/NT: target-to-non-target ratio; TR targeted radionuclide therapy; UT: untargeted; %CS: percentage
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seeds [127,165]. Seed positioning errors can develop over time, which re-
sult in a heterogeneous dose distribution consisting out of hot and cold
spots. In contrast, the injection of radiolabeled AuNPs would use much
smaller needles, which could reduce the trauma. Furthermore, the dose
delivery would be easier to control by adjusting the injection volume
and would enable the treatment of smaller tumors. Local diffusion of
small AuNPs from the injection site could facilitate the homogenization
of the radiation dose in the tumor [166,167].
Importantly, although IT injection maximizes the concentration of
AuNPs in the tumor, conjugation of targeting molecules is still useful.
For instance, conjugation of Trastuzumab, Panitumumab, cRGD,
pigallocatechin-gallate (EGCg) to AuNPs result in a >2 times prolonged
tumor retention, compared to their untargeted radiolabeled AuNPs
counterparts, which show a gradual tissue redistribution from the
breast, prostate or glioma tumor site to the liver and spleen over time
[49,157,159–161]. Furthermore, due to their relatively large size,
150 nm non-functionalized [103Pd]Pd@Au nanoseeds show a prostate
tumor xenograft retention of 5 weeks [165]. The significantly longer re-
tention of [198Au]AuNPs-EGCg (75 %ID/g after 24 h) within the prostate
tumor compared to untargeted [198Au]AuNPs (200 %ID/g after 24 h) al-
lows to inject only one third of the activity, without compromising the
tumor response (5 MBq for [198Au]AuNP-EGCg vs 15 MBq for [198Au]
AuNP-GA) [160,161].
The longer tumor retention of the targeted AuNPs leads to a higher
radiation dose delivered to the tumor. For instance, 48 h after injection
of 10 MBq [111In]In-AuNPs-Trastuzumab in a breast cancer xenograft,
the cumulative absorbed radiation dose is estimated to be 60.5 Gy, com-
pared to 28.4 Gy for untargeted [111In]In-AuNPs [156]. Similarly, 48 h
after injection of 4.5 MBq [177Lu]Lu-AuNPs-Panitumumab in a breast
cancer xenograft, the cumulative absorbed radiation dose is estimated
to be 30.37 Gy, compared to 21.86 Gy for untargeted [177Lu]Lu-AuNPs
[157]. Finally, IT injection of 8MBq of [177Lu]Lu-cRGD-AuNPs in a glioma
xenograft results in a cumulative absorbed radiation dose of 63.8 Gy
after 23 days, compared to 38.3 Gy and 16.6 Gy for [177Lu]Lu-AuNPs
and [177Lu]Lu-cRGD, respectively [49]. As a result, treatment of breast
and prostate tumor xenografts with radiolabeled, targeted AuNPs in-
hibits the tumor growth and prolongs the survival of the treated mice,
compared to the saline control (Fig. 11 A-C) [156,157,159–161,163]. In
addition, [177Lu]Lu-cRGD-AuNPs significantly reduces the glioma
tumor metabolic activity, the intratumoral blood vessels formation
and the VEGF tumoral gene expression, compared to the saline control
group, [177Lu]Lu-AuNPs and [177Lu]Lu-cRGD [49]. Moreover, Wang,
et al. confirmed the in vitro research on the possibility to combine TRT
and PTT. The intratumoral injection of [131I]I-AuNRs-PEG in breast
cancer-bearing mice delayed the tumor growth more effectively than
free iodine-131 therapy due to the higher accumulation of [131I]I-
AuNRs-PEG in the breast cancer cells. Tumor regression is observedFig. 11. Nanobrachytherapy, locally injecting radioactive AuNPs in the tumor, compared to
radioactive AuNPs. (A) SPECT/CT images of CD-1 athymic mice bearing MDA-MB-468 human
Lu-AuNP-Panitumumab or [177Lu]Lu-AuNP. (B) Tumor growth index (values shown represe
bearing mice treated with 4.5 MBq of [177Lu]Lu-AuNP-Panitumumab, [177Lu]Lu-AuNP, unlabe
saline. A-C were originally published in [157]11. (D) SPECT/CT imaging acquired 0d, 1d, 2d,
tumor bearing SCID mice. White arrows indicate tumors. (E) [18F]FDG-PET/CT images acquir
nanoseeds (middle panel) and [103Pd]Pd@Au nanoseeds (upper panel). A significant tumor F
compared to the FDG uptake of the mice treated with PBS or non-radioactive Pd@Au nanosee
images of SW1990 pancreatic tumor-bearing mice acquired various days after treatment. The
injection of AuNPs (biodegradable honeycomb-like gold nanoparticles) + BT, injection of A
tumor volume of mice 16 days after treatment with PBS, BT, AuNPs + BT, AuNPs + PTT, or A
bars are 1 cm. F-G are adapted from [192]13. 11Fig. 11 A-C were originally published in JNM
177Lu-Labeled Gold Nanoparticles: Gold Nanoseed Brachytherapy with Application for Neoa
Pages 936–42. https://jnm.snmjournals.org/content/57/6/936. © SNMMI. 12Fig. 11 D-E are a
Hassan, et al., Theranostic Nanoseeds for Efficacious Internal Radiation Therapy of Unresectabl
access article distributed under the terms of the Creative Commons BY 4.0 license (https://cr
made to the images. 13Fig. 11 F-G are adapted from F. Zhang, X. Han, Y. Hu, S. Wang, S. Liu
Strategy to Fight Deep Pancreatic Cancer, Advanced science, Vol. 6 Issue 5, 1801507, https://o
under the terms of the Creative Commons BY 4.0 license (https://creativecommons.org/license
83when IT injection of [131I]I-AuNRs-PEG is combined with photothermal
therapy using 808 nm laser irradiation (1W/cm2) (Fig. 12) [97]. Due to
the non-systemic, highly localized administration of the radiolabeled
AuNPs into the tumor, the calculated absorbed radiation doses in the
healthy organs was lower than 1.5 Gy [49,156,157]. Furthermore, the
studies did not reveal significant tissue damage, inflammation, changes
in serum alanine aminotransferase, creatinine and urea, and caused no
decrease in blood cell counts [97,156,157,159–161,163].
One of the radionuclides used in the clinic during low-dose brachy-
therapy is palladium-103. Laprise-Pelletier produced core-shell nano-
particles (<50 nm) consisting of a core of radioactive 103Pd,
surrounded by a shell of gold ([103Pd]Pd@AuNPs-PEG). In addition,
similar nanoparticles were co-labeled with the high-energy emitter
gold-198 ([103Pd]Pd@[198Au]AuNPs-PEG). Four weeks after a single IT
injection of 60 MBq of [103Pd]Pd@AuNPs-PEG or [103Pd]Pd@[198Au]
AuNPs-PEG in tumor-bearing mice, the PC3 prostate cancer xenograft
volume decreases with 56% and 75%, respectively, as compared to the
untreated controls. However, the tumor growth inhibition of [103Pd]
Pd@[198Au]AuNPs-PEG is associated with severe necrosis at the skin of
the treated mice. This observation is attributed to the emission of
high-energy electrons and the long-range high-energy photons by
gold-198, which could be a limitation of gold-198 when used for
short-range nanobrachytherapy [127]. Alternatively, Moeendarbari,
et al. produced 103Pd-coated gold nanoseeds, consisting of an 100 nm
inner gold core and an outer shell of palladium-103. The [103Pd]Pd@Au
nanoseeds significantly inhibit the prostate tumor growth and reduce
the tumor metabolic activity, 5 weeks after treatment, compared to
the saline controls (Fig. 11 D-E) [165].
In contrast to the above described studies using AuNPs radiolabeled
with lutetium-177, indium-111, gold-198 or palladium-103, there is
one study investigating the use of AuNPs (5–9 nm) radiolabeled with
the alpha-emitting 225Ac as nanobrachytherapeutic agents. The authors
IT injected glioma xenografts in mice with a very low activity (a total of
15 kBq divided over three injections) and found tumor growth retarda-
tion over a period of 22 days and three timesmore necrotic lesions in the
tumor compared to the saline-injected control group. The therapeutic
response achieved with the delivery of a low activity is due to the high
linear energy transfer (LET) of the alpha particles emitted by
actinium-225 [166].
Altogether, the IT injection of radiolabeled AuNPs in xenograft
tumor-bearing mouse models show their potential to treat localized
cancers. Importantly, next to the development of a less invasive treat-
ment procedure, AuNPs can interact with the radiation originating
from radionuclides, enhancing the dose deposition, which can increase
the efficacy of the nanobrachytherapy compared to conventional
brachytherapy. Indeed, the next paragraphs gives an overview of the
studies demonstrating that AuNPs increase the dose deposition of radio-
nuclides during brachytherapy.brachytherapy, transplanting radioactive seeds in the tumor in close proximity to non
breast cancer xenografts (white arrows) acquired 1 h or 48 h after IT injection of [177Lu
nt mean ± SD) and (C) the percentage of survival over time for MDA-MB-468 tumor
led AuNP-Panitumumab, [177Lu]Lu-DOTA-PEG-OPSS (not conjugated to AuNP) or norma
4d, 7d, 14d, 21d and 35d post-IT injection of 1.51mCi [103Pd]Pd@Au nanoseeds in PC3
ed at 0d, 7d, 21d and 35d post-IT injection of PBS (lower panel), non-radioactive Pd@Au
DG uptake reduction was observed in the mice treated with [103Pd]Pd@Au nanoseeds a
ds. White arrows indicate tumor sites. D-E are adapted from [165]12. (F) Bioluminescence
treatments are injection of PBS, brachytherapy using iodine-125 seed implantation (BT)
uNPs + photothermal therapy (PTT), and injection of AuNPs + PTT + BT. (G) Relative
uNPs + PTT + BT. Insets: corresponding digital pictures of tumor post treatments. Scale
. S. Yook, Z. Cai, Y. Lu, M. A. Winnik, J. P. Pignol and R. M. Reilly. Intratumorally Injected
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dapted from S. Moeendarbari, R. Tekade, A. Mulgaonkar, P. Christensen, S. Ramezani, G
e Solid Tumors, Sci Rep, Vol. 6, 20614, https://www.nature.com/articles/srep20614, Open
eativecommons.org/licenses/by/4.0/). Copyright (2016) The Author(s). No changes were
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gold nanoparticles during brachytherapy
Dose enhancementmediated byAuNPs has beenwell established for
external X-ray irradiation as discussed in Section 1.3.2 of the Introduc-
tion. Similarly, multiple Monte Carlo simulations demonstrate dose en-
hancement when AuNPs are introduced in a tumor phantom region in
close proximity to a radionuclide source or seeds. The most commonly
studied radionuclides for brachytherapy purposes are the low-dose
rate emitting iodine-125, palladium-103 and cesium-131, and the
high-dose rate emitting ytterbium-169, iridium-192 and gold-198. The
dose enhancement factor (DEF) is calculated as the ratio of the dose in
the tumor or tissue region with and without the presence of AuNPs.
TheDEF strongly depends on the radiation source energy, theAuNP con-
centration in the tumor, the AuNPs distribution in the phantom, and the
AuNP size. First, as shown in Supplementary Table 1, a higher DEF is
reached as the AuNP concentration in the tumor increases [168–180].
In addition, higher DEF values are especially obtained for the low-
energy emitting radionuclides palladium-103 (21 keV) and iodine-125
(29 keV), compared to the high energy emitting radionuclides
ytterbium-169 (92.7 keV) and iridium-192 (354 keV). These results
are attributed to the stronger andmore important photoelectric absorp-
tion of AuNPs after interaction with low energy photons, causing a dose
enhancement by the release of photoelectrons, Auger electrons and
characteristic X-rays [170–175,178,180–182]. As a result, the calculated
DEF increaseswith an increasingdistance from the high-energy radioac-
tive source, because of the shift in the emission spectra towards lower
energies [169,174,182]. Although the photoelectric absorption is most
efficient and abundant when using energies below the K-edge of gold
(80.7 keV, the binding energy of the innermost and most strongly
bound electrons), the emitted secondary electrons have a low energy
and a high LET. Therefore, their traveling range is short (<100 μm),
while the microscopic DEF in the area closely surrounding the AuNP is
high, >80 [183]. Due to the limited travel range of the low-energy,
high-LET electrons, small-sized AuNPs are required to minimize the in-
ternal absorption of the secondary electrons inside the nanoparticles
and internalization of the AuNPs is necessary to cause cell damage. On
the other hand, for high-energy photon sources, the energy of the re-
leased photoelectrons is higher, but their LET is lower. Therefore, the
electrons can cross-fire across multiple cells. As a result, higher concen-
trations of AuNPs are required to increase the dose enhancement, while
AuNP size and cellular localization are less relevant [181,183].
Importantly, multiple studies demonstrate that the presence of
AuNPs not only increases the dose inside the tumor, but also shields
healthy tissue from low-dose irradiation and thus decreases the dose
delivery outside the tumor region, compared to brachytherapy without
AuNPs [168–170,172,174,176,179,182,184–186]. For instance, Brivio,
et al. studied the dose enhancement effects caused by a uniform and
non-uniform distribution of AuNPs during prostate cancer brachyther-
apy with 125I-seeds [186]. More specifically, they compared the DEFs
when the AuNPs were uniformly distributed in the prostate volume,
confined at the seeds or located in between the seeds. Positioning the
AuNPs between the seeds is the most beneficial scenario, since it causes
a dose enhancement in the whole prostate. Importantly, the study
highlighted that in all three distribution patterns, the urethra and rec-
tum are spared and receive only 1/3 of the standard brachytherapy
dose without AuNPs. This radiation attenuation effect observed in theFig. 12. Combination therapy. (A) The specific characteristics of radiolabeled AuNPs enable th
therapeutic radiation dose to the tumor, while the surface plasmon resonance of the AuNPs e
MCF-7 tumor-bearing mice acquired 1 h, 10 h, 18 h and 24 h after IT injection of [131I]I(0)-A
AuNRs-PEG, or [131I]I(0)-AuNRs-PEG. (D) Tumor growth rate after treatment with PBS, free N
volumes were normalized to their initial size. The error bars represent the standard deviatio
tumor growth more effectively. Upon 808 nm laser irritation (0.5 W·cm−2), the tumor tempe
within 2 min and the tumor growth delayed greatly. When combining the radionuclide t
completely suppressed and the mice survival time greatly increases. Adapted from [97]14. 14F
P. Wang, W. Sun, Q. Wang, J. Ma, X. Su, Q. Jiang, et al., Iodine-Labeled Au Nanorods with Hig
Pages 1374–1381. Copyright (2019) American Chemical Society.
85healthy tissues is attributed to the high-Z AuNPs, which absorb the ra-
dionuclide X-rays and emit low-energy electrons. These low-energy
electrons are in turn rapidly stopped within the nano- or micrometer
range from the AuNPs [186]. Overall, the Monte Carlo simulations
show that AuNPs might be a promising tool to increase the therapeutic
ratio of brachytherapy and spare the surrounding healthy tissues.
In order to confirm and validate Monte Carlo simulation results,
Khosravi, et al. embedded 15 nm AuNPs in a polymeric gel (Magic-f)
that was located in the prostate region of a plexiglas pelvic phantom.
The authors performed dosimetric measurements after irradiation of
the gel using 192Ir-brachytherapy sources [187] The experimental re-
sults showed a DEF of 1.14 when AuNPs were present in the gel,
which was in good agreement with the DEF estimated by the MCNP5
Monte Carlo calculation [187].
3.3.5. In vitro and in vivo radiosensitization of non-radiolabeled AuNPs
during brachytherapy
The numerous simulation studies described above are supported by
several experimental in vitro and in vivo studies. For instance, Shahhoseini,
et al. inserted 192Ir-sources and electronic brachytherapy sources (eBx®)
generating low-energy 50 kV X-rays into applicator ducts built under a 6-
well plate. The wells were seeded with A549 lung cancer cells or Du145
prostate cancer cells, which were exposed to 1 mM AuNPs (15 nm) for
24 h before irradiation. According to colony forming unit assays, pre-
exposure of cells to AuNPs caused DEFs of 1.54 and 2.06 for A549 cells
and of 1.64 and 2.90 for Du145 cells after irradiation with iridium-192
and eBx, respectively. This in vitro study confirms the results of the theo-
retical studies demonstrating that higher DEF values are reached with
low-energy emitting brachytherapy sources [188]. Furthermore, γH2AX
staining shows that HeLa cells incubated with 0.2 mg/ml of 50 nm
AuNPs and irradiated with a 125I-seeds plaque exhibit more unrepaired
DNA damage after 24 h, with a DEF value ranging from 1.7 to 2.3, com-
pared to irradiated cells without AuNPs [189]. In line with these results,
1 h after irradiation with an erbium filtered 250kVp beam mimicking
the photon radiation spectrum of ytterbium-169, goserelin-conjugated
gold nanorods (gAuNRs) induce significantlymoreγH2AX foci in prostate
cancer cells that overexpress the gonadotropin releasing hormone
(GnRH) receptor compared to the irradiated control cells and irradiated
cells exposed to untargeted AuNPs. Moreover, the growth rate of PC3
prostate cancer xenografts is significantly reduced over a period of
70 dayswhen treatedwith IV injected gAuNRs and irradiatedwith the er-
bium filtered X-ray beam, compared to irradiation alone (a tumor volume
of 1.87 cm3 vs 4.01 cm3, respectively) [190]. Similarly, a 2 h-incubation of
Na/I symporter-expressing B16F10 melanoma cells or DHD/K12/TRb co-
lorectal cancer cells with 25 μg/ml of polymer grafted-AuNPs significantly
sensitizes the cells to 131I-exposure (0.1–0.2MBq). Furthermore, the com-
bination of IT injected polymer-grafted AuNPs and IP 131I-treatment at-
tenuated the tumor growth of xenografted melanoma cells by 34% over
131I-treatment alone [191]. Finally, a small (but non-significant) decrease
of the SW1990 pancreatic xenograft volume was observed 16 days after
treatment with IV injected AuNPs and 125I-seed implantation, compared
to 125I-brachytherapy alone (Fig. 11 F-G) [192].
3.3.6. Radiosensitization mechanism of radiolabeled gold nanoparticles
As described by the theoretical, in vitro and in vivo studies above,
AuNPs are promising tools to enhance the dose deposition of radionu-e combination of different treatments. IT administration of radiolabeled AuNPs deliver a
nables photothermal therapy, increasing the tumor temperature (B) SPECT/CT imaging o
uNRs-PEG. (C) Thermal imaging of MCF-7 tumor bearing mice after IT injection of PBS
a[131I]I, AuNRs-PEG + laser, [131I]I(0)-AuNRs-PEG, [131I]I(0)-AuNRs-PEG + laser. Tumo
n of 5 mice per group. Compared with free Na[131I]I, [131I]I(0)-AuNRs-PEG inhibited the
rature of the tumor injected with AuNRs-PEG or [131I]I(0)-AuNRs-PEG increased to 50 °C
herapy with photothermal therapy using [131I]I(0)-AuNRs-PEG, the tumor growth is
ig. 12 B-D are adapted with permission from ACS Applied Nano Materials, Vol. 2 Issue 3
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AuNPs that were placed in the vicinity of radioactive seeds. This ap-
proach would still require the invasive implantation of the radioactive
seeds as explained before. Therefore, Laprisse, et al. studied the macro-
scopic and microscopic dose enhancement of 103Pd-radiolabeled
AuNPs that were injected in prostate cancer xenografts [167]. Macro-
scopically, the radiolabeled AuNPs exhibit a smaller area of energy de-
position compared to the conventional brachytherapeutic seeds due to
the attenuation of the 103Pd-photons by the AuNP cloud. This attenua-
tion effect could increase treatment precision and reduce dose deposi-
tion in healthy tissue. In their microdosimetric approach, the authors
used TEM imaging to take into account the specific intracellular biolog-
ical structures and well as the strong agglomeration of the radiolabeled
AuNPs inside intracellular vesicles and their heterogeneous distribution
in the tumor cells. In the very close vicinity of the AuNPs, the presence of
gold enhances the dose depositionwith a DEF of 25, compared to 103Pd-
coreswithout AuNPs. There is a sharp fall-off of the DEFwith an increas-
ing distance, which reduces to 1 when the distance from the AuNPs
reaches 2 μm. Importantly, since the radiolabeled AuNPs are strongly ac-
cumulated inside intracellular vesicles, there was no strong dose en-
hancement (DEF = 1) found in the cell nuclei. Nevertheless, IT
injection of the [103Pd]Pd@AuNPs-PEG showed strong tumor volume
control [127]. Therefore, besides the physical dose enhancement, indi-
rect damage via ROS production and the biological radiosensitization,
which is discussed in detail in the introduction are potential leading
mechanisms of the radiolabeled AuNPs to increase the therapeutic effi-
cacy of radionuclide therapy.
Although IT injection of radiolabeled AuNPs show promising exper-
imental results in vivo, from a clinical point of view, the use of
radiolabeled AuNPs as an alternative for brachytherapy seeds remains
challenging. In order to treat a human tumor, which is much larger
than an in vivo xenograft, multiple IT injections of radiolabeled AuNPs
in the tumor are required. These IT injections need to be spatially dis-
tributed with a high accuracy to minimize dose deposition heterogene-
ities in the tumor [193]. Therefore, Lai, et al. supports the implantation of
nanoparticle release devices, which are loaded with a high concentra-
tion of radiolabeled AuNPs that are released into the surrounding
tumor tissue. The authors describe this as an intermediate option com-
bining the precise positioning using conventional seed implantation
techniques and the advantage of homogenizing the dose deposition
through the sustained delivery and diffusion of radiolabeled AuNPs
out of the device [194]. Previous studies showed that during iodine-
125 irradiation, the DEF at a close distance from the nanoparticle release
device (5 mm) increases in function of time, due to the continuous
AuNPs released from the device. Furthermore, the use of small-sized
AuNPs (2–5 nm) results in higher DEFs due to their high release rate
and homogeneous diffusion rate, compared to larger AuNPs (>15 nm)
[193,195]. Lai, et al. studied the dose distribution of AuNPs labeled
with lutetium-177, yttrium-90 and indium-111 from nanoparticle re-
lease devices or IT injected. The higher electron emitter yttrium-90 re-
sulted in a greater penetration and delivered a more homogeneous
dose distribution than the lower energy electron emitters lutetium-
177 and indium-111. Furthermore, the dose distribution of radiolabeled
AuNPs originating from a nanoparticle release device implanted in a
tumor xenograft in vivo remains concentric around the device, while
IT injection of the radiolabeled AuNPs results in irregularly shaped
dose distribution, which are difficult to predict over time. Therefore,
the authors highlighted the potential of the nanoparticle release device
to improve the conventional brachytherapy strategies by providing a
more predictable and homogeneous dose distribution to the tumor
[194].
4. Conclusions and perspectives
In this review,we gave an overviewon the radiolabeling processes of
AuNPs and the potential of radiolabeled AuNPs to improve current86nuclear imaging and therapy, taking into account the administration
method, the biodistribution profile, tumor uptake, intratumoral distri-
bution and tumor retention. We highlighted that targeted, radiolabeled
AuNPs enhance the tumor uptake and retention, causing a better tumor
control compared to their radiopharmaceutical analogs without AuNPs.
Furthermore, radiolabeled AuNPs enable the use of multimodal imaging
platforms for the visualization of their maximal tumor uptake to initiate
photothermal therapy, to increase the effectiveness of external beam ra-
diotherapy, or to define sentinel lymph nodes.
A large majority of the radiolabeled AuNPs that are administered sys-
temically cause a sub-optimal biodistribution with a high and prolonged
accumulation in non-targeted healthy tissues, such as in the liver, spleen
and kidneys, which can result in an adverse dosimetric profile. In order
to avoid the strong sequestration of the AuNPs by the RES, radiolabeled
AuNPs as therapeutic agents are usually assessed after IT injection. This
shifted our focus to the use of AuNPs in nanobrachytherapy. It is well
established by numerous Monte Carlo simulations and experimental
studies that non-radioactive AuNPs enhance the dose deposition of con-
ventional brachytherapy seeds and reduces the dose deposition in healthy
tissue due to the radiation absorption. However, the number of studies fo-
cusing on the dose enhancement using radiolabeled AuNPs, despite their
ability to control tumor growth, remains limited. Furthermore,wewant to
point out that inmanyexperimental dose enhancement studies, the inter-
action between high-Z AuNPs and the radionuclide radiation is often the
only mechanism stated for the increased effectiveness of the (brachy)ra-
diotherapy. This despite the numerous studies showing that AuNPs also
have biological effects in cancer cells. Indeed, exposure of cancer cells to
AuNPs alone can cause mitochondrial dysfunction, oxidative stress, in-
creased DNA damage, lysosomal dysfunction, etc. These biological effects
alone may not be lethal to the cancer cells, but certainly can increase the
radiation sensitivity of the cancer cells and thus sensitize the cells to the
radionuclide therapy. The dose enhancement studies discussed in this re-
view often conclude that low-dose radionuclides are a good choice to
achieve a strongdose enhancement from theAuNPs.However, the biolog-
ical radiosensitization of the AuNPs should not be underestimated and
thus could be a valuable reason to explore the use of AuNPs radiolabeled
withhigh-energy radionuclides to improve targeted radionuclide therapy.
The intratumoral delivery of radiolabeled AuNPs is less useful for the
detection and imaging of cancer cells. However, besides the delivery of
radionuclides, radiolabeled AuNPs also have the potential to carry chemo-
therapeutic drugs,mediate photothermal ablation and radiosensitize can-
cer cells, which makes them valuable tools to overcome radioresistance
and/or chemoresistance cancer cells.
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